

Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates
--Manuscript Draft--

Manuscript Number:	PONE-D-12-00008R1
Article Type:	Research Article
Full Title:	Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates
Short Title:	Cell-based EV71 vaccine candidate
Corresponding Author:	Pele Choi-Sing Chong, Ph.D. National Health Research Institutes Zhunan Town, Miaoli County TAIWAN
Keywords:	Hand-Foot-Mouth Diseases; enterovirus 71; inactivated whole virion vaccine; serum-free culture technology; cross-neutralizing antibody
Abstract:	<p>Background: Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia and now is being recognized as an important neurotropic virus. Effective medications and prophylactic vaccine against EV71 infection are urgently needed. Based on the success of inactivated poliovirus vaccine, a prototype chemically inactivated EV71 vaccine candidate has been developed and currently in human phase 1 clinical trial.</p> <p>Principal Finding: In this report, we present the development of a serum-free cell-based EV71 vaccine. The optimization at each step of the manufacturing process was investigated, characterized and quantified. In the up-stream process development, different commercially-available cell culture media either containing serum or serum-free was screened for cell growth and virus yield using the roller-bottle technology. VP-SFM serum-free medium was selected based on the Vero cell growth profile and EV71 virus production. After the up-stream processes (virus harvest, diafiltration and concentration), a combination of gel-filtration liquid chromatography and/or sucrose-gradient ultracentrifugation down-stream purification processes were investigated at a pilot scale of 40 liters each. Although the combination of chromatography and sucrose-gradient ultracentrifugation produced extremely pure EV71 infectious virus particles, the overall yield of vaccine was 7-10% as determined by a VP2-based quantitative ELISA. Using chromatography as the downstream purification, the virus yield was 30-43%. To retain the integrity of virus neutralization epitopes and the stability of the vaccine product, the best virus inactivation was found to be 0.025% formalin-treatment at 37oC for 3 to 6 days. Furthermore, the formalin-inactivated virion vaccine candidate was found to be stable for >18 months at 4oC and a microgram of viral proteins formulated with alum adjuvant could induce strong virus-neutralizing antibody responses in mice, rats, rabbits, and non-human primates.</p> <p>Conclusion: These results provide valuable information supporting the current cell-based serum-free EV71 vaccine candidate going into human Phase I clinical trials.</p>
Order of Authors:	<p>Ai-Hsiang Chou</p> <p>Chia-Chyi Liu</p> <p>Cheng-Peng Chang</p> <p>Meng-Shin Guo</p> <p>Shih-Yang Hsieh</p> <p>Wen-Hsueh Yang</p> <p>Hsin-Ju Chao</p> <p>Chien-Long Wu</p> <p>Ju-Lan Huang</p>

	Min-Shi Lee
	Alan Yung-Chi Hu
	Sue-Chen Lin
	Yu-Yun Huang
	Mei-Hua Hu
	Yen-Hung Chow
	Jen-Ron Chiang
	Jui-Yuan Chang
	Pele Choi-Sing Chong, Ph.D.
Suggested Reviewers:	<p>Hiroyuki Shimizu, PhD Director, National Institute of Infectious Diseases, Japan hshimizu@nih.go.jp Professor Shimizu who has been working on enterovirus for long time, is the key scientist identifying the receptor of EV71. He also has great interest in vaccine development against EV71. Therefore, he is fully qualified as a reviewer of this manuscript.</p> <p>Heidi J Larson, PhD Professor, London School of hygiene and Tropical Medicine heidi.larson@lshtm.ac.uk Professor has great interest in polio eradication and expertise in enterovirus virology and vaccinology, so she is qualified to review our paper.</p>
Opposed Reviewers:	
Response to Reviewers:	<p>February 17, 2012.</p> <p>Dear Professor Yi Guan:</p> <p>First of all, we thank you and reviewers for your diligent effort to evaluate the credibility and the potential values of our paper. Please find below our responses to the Reviewers' comments:</p> <p>Reviewer #1:</p> <p>This study by Chou et al. describes the development of an enterovirus 71 (EV71) vaccine at a pilot scale based on the serum-free growth of EV71 in Vero cells and its subsequent inactivation and purification. The authors have demonstrated that an inactivated EV71 E59 vaccine (genotype B4) elicit a strong neutralising response not only against genotype B4 but also cross-reacting activity against other EV71 genotypes. Although this is not a ground-breaking area of research, and similar publications have already been described recently (Bek et al 2011, Dong et al 2011, cited within the text), I consider this paper an interesting piece of data for both clinical and non-clinical researchers working in the field. EV71 is a very important human pathogen of tremendous relevance for the global public health, and the development of efficient vaccines to control it represents an important step forward. In summary, the experiments have been properly conducted and support the conclusions reached by the authors.</p> <p>However, the paper is very poorly written. Apart from considerable grammatical errors across the text, there are loads of typos and other non-grammatical mistakes which suggest the authors have not paid sufficient attention during the preparation of this manuscript. As an example: part of the text (page 4) is in a red coloured font and especially very bad written (it seems to have been directly copied from elsewhere), references 2 and 3 show typos in the publication dates (years 010 and 202?), and figure 5 cited in the text does not appear attached to the text. The authors may want to improve the clarity and the quality of the text to be considered for its publication in PLoS ONE. Additionally, I have also other concerns affecting the scientific data presented here that should be addressed by the authors.</p> <p>Response: We thank the Reviewer pointing out our mistakes that have been corrected.</p>

It is a typo error, the figure 5 should be written as the figure 4. The revised manuscript has been edited by an English speaking scientist.

My final decision is timidly recommend this paper with the condition of making large improvements in the text and answering the several major critique points listed below.

Major points:

1. The manuscript introduction lacks a detailed description on the EV71 and/or picornavirus capsid protein expression, maturation and crystal structure. Within the text you mention VP1, VP2, VP4, VP0 without providing with any background information on these proteins. Special emphasis on VP0 cleavage into VP2 and VP4 as a key capsid maturation step simultaneous to viral RNA encapsidation (at least in other picovornaviruses) should be provided. References should also be included. No information provided either on the actual EV71 cellular receptors (and other picornaviruses). I think this information is relevant for putting the data within context.

Response: The comment from the Reviewer is well taken, so we have added the information and references into the Introduction section (red color). The cleavage of VP0 into VP2 and VP4 has been shown as a key capsid maturation step and also is important to viral RNA encapsidation [8,10].

Two different membrane proteins, human P-selectin glycoprotein ligand-1 (PSGL-1) [14] and human scavenger receptor class B, member 2 (SCARB2) [15] have been identified as cellular receptors for EV71. Transgenic mice carrying these genes are being engineered and should be useful for HFMD vaccine development.

2. Experiment in Figure 2A is not well explained. Sentence in page 10 is terribly confusing. Do you mean you seeded this amount of cells or that you infected that amount of cells? They represent different scenarios and a different interpretation can be made. Anyway, it is a bit contradictory that only a 2-fold difference in the number of cells resulted in 10-fold differences in virus titres at different time points. Were these TCID50 carried out in triplicate? If so, I'd suggest carrying out a replica of this experiment to show if the same effect can be reproduced.

Response: We thank the Reviewer pointing out the unclear statement. In the revised manuscript, we re-write the figure legend of Figure 2A: The T-flask was seeded with either $1.0\sim 1.5 \times 10^6$ or $2.0\sim 2.5 \times 10^6$ Vero cells, then after 2-3 days the cells were infected by the different ratio of E59/EV71 virus.

3. In Figure 3, inactivation at 25 C has been adjusted to a line, but it seems not to follow linear progression. I think it would be more precise to calculate the inactivation tendency and kinetics only with later time points (from 24 hours onwards) or alternatively adjust the inactivation kinetics to a curve.

Response: We have revised the figure 3 according to the Reviewer's suggestion and calculate the inactivation tendency and kinetics only with later time points (from 24 hours onwards). Therefore, the time required for full inactivation will be 12.6 days for 25 C. We have revised this new data in the text.

4. Page 15, line 22. It is claimed that virus titer is decreased 2- to 8-fold in cross-neutralization experiments. Nevertheless, if I am not wrong, sera from BALB inoculated with lot 1, presented 14-fold differences in neutralizing reference E59 strain with respect to B5 strain. Please clarify this point.

Response: We thank the Reviewer pointing out the mistake in calculation. We revised the sentence: Although the neutralization titer was decreased (2- to 14-fold), sera from mice immunized twice with EV71 vaccine bulk were capable of cross-neutralizing other isolates from B4, B5 sub-genotype and C4 genotype (Table 2).

5. Vaccine lots present a large proportion of VP0 which is comparable to the levels detected of VP2. This fact suggests that about a 50% of capsid proteins are incompletely mature. In other picornaviruses it has been demonstrated that RNA encapsidation is coetaneous to VP0 cleavage into VP2 and VP4 and subsequent capsid maturation. It would be interesting to demonstrate if vaccine lots used contain only capsids or they are mixtures of capsids and unassembled pentamers. I'd

recommend carrying out a WB analysis with further purified samples, e.g: ultra-pure EV71 mentioned in page 13, line 42, to determine if VP0 is present in unassembled capsid units or if also found in full-capsid structures.

Response: The Reviewer is totally right on the issue that we found infectious EV71 viruses produced from the Vero cells grown in serum-free medium to be around 30% compared to the defective viral particle. As shown in Figures 2 and 3 of our previous report [10], the purified infectious EV71 virus was found to consist of all 4 structural proteins VP1, VP2, VP3 and VP4. In contrast, VP0, VP1 and VP3 protein bands were found to be the major components in the defective viral particles in the SDS-PAGE and Western blot analysis.

6. NO FIGURE 5!!!! Please upload it.

Response: It is a typo error, the figure 5 should be written as the figure 4.

Minor points:

-Page 4: Change to black font. Remove list numbers and change the text to past tense. Include animal experiments procedures with mice, rat and rabbit elsewhere.

Response: We had revised the monkey experimental procedure according to the Reviewer's suggestion.

-Page 6, line 1. Change inoculated by seeded. Line 2, At each time point, cell culture was performed??. This sentence makes no sense. Please clarify. Line 5, change cell counts were performed by cell counting was performed. Line 16, Do you want to mean 'EV71 stocks were produced using the roller bottle technology AND purified using?..

Response: We thank the Reviewer pointing out our mistakes. We had revised the procedure according to the Reviewer's suggestion.

-Page 6, 7 and along the text, performed is constantly and redundantly used. You may want to use synonyms such as carry out, develop?

Response: We had revised the manuscript according to the Reviewer's suggestion.

-Page 7 and through the rest of the manuscript, many sentences finish without a dot. Please correct this.

Response: We had revised the manuscript according to the Reviewer's suggestion.

-Page 7, line 42. Use abbreviation for millilitre (mL). Page 8, line 32. Diluted. Page 10, line 52. The highest virus titer WAS 2 x 10⁷.

Response: We had revised the manuscript according to the Reviewer's suggestion.

-Page 14, line 10. I suggest replacing 'no infectious EV71 particle was observed' by 'no infectivity was detected'. Line 15, I'd remove particle since this cannot be physically observed.

Response: We had revised the sentence according to the Reviewer's suggestion.

-Page 15, lines 34-42. This sentence is grammatically wrong. Please amend it.

Response: We had revised the manuscript according to the Reviewer's suggestion. "The titers of infectious virus particles in the supernatants harvested from three cGMP lots were found to be 11.70, 6.31, and 10.5 × 10⁶ TCID₅₀ units per mL for Lot #1, 2, and 3, respectively (Table 1). VP2 epitope contents were measured by Q-ELISA and found to be 11.9, 7.73, and 8.1 units of VP2 per mL in Lot #1, 2, and 3, respectively".

-Page 16, lines 29-32. This sentence makes no sense. Amend it.

Response: We had revised the sentence according to the Reviewer's suggestion. "These results suggest that the un-assembled VP2 antigens were not removed from

the virus concentrate at the 100 kDa TFF step”.

-Too many typos within the References section. I recommend the authors to use a citation tool programs (i.e. Endnote or similar).

Response: We had revised the manuscript according to the Reviewer's suggestion.

-Figure legends are poor. Please include more information about the experiments carried out in each of them. Improve the quality in Figures 1, 2A, 2B, 3. Please use the same font type and size following indications provided in PLoS ONE guidelines. Please use internationally accepted units in the abscissa (1.E+05 is not a valid measure unit).

Response: We had re-written the figure legends and improved the quality of figures in the revised manuscript according to the Reviewer's suggestion.

Reviewer #2: The authors describe the production of Enterovirus 71(EV71) vaccine candidate and monitoring of the production steps by infectious titer, total protein concentration and Vp2 content.

My questions are as follow:

1. Why didn't the authors use the bioreactor system and cytodex beads to grow the virus like they did in the referenced papers(see ref. 17 in the draft) instead of flasks and roller bottles.

In the papers and also related papers they pretty much characterized the vero cell-EV71 system in the same serum-free medium. Maybe simply it is timing of preparing and submitting the drafts to the different journals.

In regarding with the cells, cells in suspension may be suitable in production of vaccine.

Response: The Reviewer has pointed out our frustration, issues and constraints working in a non-profit organization and funding come from government. In the original EV71 vaccine development program, we would like quickly going into human clinical trials using roller bottle technology to produce EV71 from Vero cell grown in serum-containing medium. In the middle of process development, the reviewers from Taiwan FDA and government funding agents suggested to use the serum-free medium for the cell culture. Therefore, we switched to produce the GMP-grade clinical materials in serum-free medium and reported in this manuscript. The results generated from the serum-containing medium studies were reported in the reference #19. Three years ago, our cGMP facility did not have a 30-L Bioreactor for the process development and the 5-L bioreactor used in the Research laboratory was too small for pilot scale production and could not produce enough materials for human clinical trials. For these reason, the first generation of EV71 vaccine is produced from roller bottle and serum-free medium.

2. Any of the monkeys was removed from the study due to sickness or any other reasons for that matter.

Response: No, all monkeys immunized with the EV71 vaccine candidate are healthy and have no problems.

3. Tables 1 and 2 need to be simplified, especially table 1. In the table 1 the unit of total volume says (L), if it's true, 41 liters would be awfully large. I think it's a typo. If it's meant to be mL, then 41mls would be too little, since 200mls per roller bottle were used.

Response: The unit of total volume is liter and about 40 liters of virus harvest were produced from each pilot- scale production run (200 x 200 mL).

4. It would be nice to know how many infectious viruses were used to immunize these animals in the table 2.

Response: Since we use formalin-inactivated EV71 vaccine candidate for the

immunizations, so there would be no live or infectious viruses. Based on the overall recovery yield, we could estimate each microgram of viral proteins containing 2×10^4 TCID50 infectious unit

5. Have comparison studies between with and without alum adjuvant been done?

Response: We had studied the effect of alum adjuvant in the vaccine efficacy and reported in the reference #19. The formalin-inactivated EV71 vaccine candidate formulated in aluminum phosphate (alum) elicited 3 to 5-fold higher virus neutralizing antibody responses in mouse model.

Following are more specific comments:

Page 3, line 41-51 How does formalin-inactivated EV71 in this study relate to heat-inactivated EV71?

Response: We had performed the comparison studies between the formalin-inactivated and the heat-inactivated EV71 vaccine candidates produced from the serum-containing medium, and found the neutralization titers to be similar. There is a problem associated with the heat-inactivated EV71 that could reverse to become infectious again under long term storage. For the safety issue, we select formalin-inactivated EV71 vaccine candidate.

Page 4, line 24 What is SPF?

Response: SPF means specific pathogens free.

Page 5, line 1 Change from a high-risky pathogen to having a high-risk pathogen. What are high-risk pathogens?
line 41 What is cGMP?

Response: We had revised the manuscript according to the Reviewer's suggestion. cGMP means current Good Manufacturing Practices.

Page 6, line 2-5 Meaning of "At each time point....in triplicate" is not clear.

Response: We had revised the manuscript: "At each time point, cell counts were performed in triplicate".

Page 8, line 46 "goat anti-rabbit IgG" Shouldn't it be conjugated to some kind of enzyme or labels?

Response: Goat anti-rabbit IgG is conjugated to peroxidase. We had revised the sentence in the manuscript:

Page 10, line 53-56 Were the cells in the roller bottles and/or flasks checked for growth phase? were they formed a confluent layer or sub-confluent layer? Virus yield might have been due to the growth phase of the cells.

Response: The roller bottles were inoculated sub-confluent state and virus was added when there was ~80-90% confluent. The Reviewer could be right that high virus yield might have been due to the growth phase of the cells.

Page 11, line 3-5 MOI is very low to me. The virus was harvested before CPE had appeared? Deliberately avoided CPE due to host proteins?

Response: Yes, the virus was deliberately harvested before CPE to avoid the host proteins contamination.

We hope with all these changes that will be satisfactory to you and the Reviewers.

Best regards.

1 February 17, 2012.

2
3 Dear Editor,

4
5 We have revised the manuscript entitled “Pilot Scale Production of Highly Efficacious
6 and Stable Enterovirus 71 Vaccine Candidates” according to the Editor and
7
8 Reviewers’ comments and suggestions. We would like you to consider this manuscript
9
10 for publication in PLoS ONE. All authors have reviewed and approved this version of
11
12 the manuscript, and that it is not currently submitted for publication elsewhere.
13
14
15

16
17 Thank you and we are looking forward to hearing the positive responses from
18
19 you.
20

21
22 Best regards,

23
24 Pele Choi-Sing Chong. Ph.D.

25
26 Director

27
28 Vaccine Research and Development Center

29
30 National Institute of Infectious Diseases and Vaccinology

31
32 National Health Research Institutes

33
34 No.35, Keyan Road, Zhunan Town,

35
36 Maioli County, Taiwan, 350.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates

1
2
3
4 Ai-Hsiang Chou^{a,1}, Chia-Chyi Liu^{a,1}, Cheng-Peng Chang^a, Meng-Shin Guo^a, Shih-Yang Hsieh^a,
5
6 Wen-Hsueh Yang^a, Hsin-Ju Chao^a, Chien-Long Wu^a, Ju-Lan Huang^a, Min-Shi Lee^a, Alan Yung-Chi
7
8 Hu^a, Sue-Chen Lin^a, Yu-Yun Huang^a, Mei-Hua Hu^a, Yen-Hung Chow^a, Jen-Ron Chiang^b, Jui-Yuan
9
10 Chang^a, and Pele Chong^{a,c,*}
11
12

13
14 ^aVaccine R&D Center, National Institute of Infectious Diseases and Vaccinology, National Health
15
16 Research Institutes, Zhunan Township, Miaoli County, Taiwan 350. ^bVaccine Center, Taiwan
17
18 Centers for Diseases Control, Taipei, Taiwan. ^cGraduate Institute of Immunology, China Medical
19
20 University, Taichung, Taiwan.
21
22

23
24 ¹These authors equally contributed to this work.
25

26
27 *Corresponding authors: Pele Chong, Vaccine R&D Center, National Institute of Infectious Diseases
28
29 and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County, Taiwan
30
31 350. 886-37-246 166, ext 37800; Email: pelechong@nhri.org.tw (PC).
32
33
34

35 *Running title:* Cell-based EV71 vaccine candidate
36

37
38 *Key Words:* Hand-Foot-Mouth Diseases, Enterovirus 71, inactivated whole virion vaccine,
39
40 serum-free culture technology, cross-neutralizing antibody
41

42 *Author Contributions:*

43 Conceived and designed the experiments: J-YC, Y-CH, C-CL, S-YH, A-HC, PC.

44 Performed the experiments: J-YC, C-PC, C-CL, M-SG, C-YC, A-HC, S-CL, H-JC, C-LW, Y-YH,
45
46 W-HY, J-LH, S-YH.
47

48 Analyzed the data: J-YC, M-SG, C-CL, S-YH, Y-CH, H-JC, M-SL, Y-HC, J-LH, A-HC, PC.

49 Contributed reagents/materials/analysis tools: J-RC, J-YC, M-SG, C-CL, Y-HC, C-LW, A-HC,
50
51 M-SL, J-LH, S-YH
52

53 Wrote the paper: A-HC, C-CL, PC.
54
55
56
57
58
59
60
61
62
63

Abstract

Background: Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia and now is being recognized as an important neurotropic virus. Effective medications and prophylactic vaccine against EV71 infection are urgently needed. Based on the success of inactivated poliovirus vaccine, a prototype chemically inactivated EV71 vaccine candidate has been developed and currently in human phase 1 clinical trial.

Principal Finding: In this report, we present the development of a serum-free cell-based EV71 vaccine. The optimization at each step of the manufacturing process was investigated, characterized and quantified. In the up-stream process development, different commercially-available cell culture media either containing serum or serum-free was screened for cell growth and virus yield using the roller-bottle technology. VP-SFM serum-free medium was selected based on the Vero cell growth profile and EV71 virus production. After the up-stream processes (virus harvest, diafiltration and concentration), a combination of gel-filtration liquid chromatography and/or sucrose-gradient ultracentrifugation down-stream purification processes were investigated at a pilot scale of 40 liters each. Although the combination of chromatography and sucrose-gradient ultracentrifugation produced extremely pure EV71 infectious virus particles, the overall yield of vaccine was 7-10% as determined by a VP2-based quantitative ELISA. Using chromatography as the downstream purification, the virus yield was 30-43%. To retain the integrity of virus neutralization epitopes and the stability of the vaccine product, the best virus inactivation was found to be 0.025% formalin-treatment at 37°C for 3 to 6 days. Furthermore, the formalin-inactivated virion vaccine candidate was found to be stable for >18 months at 4°C and a microgram of viral proteins formulated with alum adjuvant could induce strong virus-neutralizing antibody responses in mice, rats, rabbits, and non-human primates.

Conclusion: These results provide valuable information supporting the current cell-based serum-free EV71 vaccine candidate going into human Phase I clinical trials.

Introduction

1
2 Enterovirus 71 (EV71) infections have recently emerged in Asia as a serious cause of hand, foot
3 and mouth disease (HFMD) in children that can lead to severe neurological complications and death
4 [1-4]. Different types of vaccines against EV71 infection are being developed [4-6] and promising
5 candidates are being evaluated in human Phase 1 clinical trials [6]. EV71 is a non-enveloped RNA
6 virus of the family *Picornaviridae*, first identified in 1969 in the United States [7]. The EV71 virus
7 particle contains a single molecule of plus sense ssRNA (7.5-8.5 kb). The complete nucleotide
8 sequence of the EV71 prototype strain BrCr has been determined and contains four structural
9 proteins: VP1, VP2, VP3 and VP4 [8,9]. The cleavage of VP0 into VP2 and VP4 has been shown as
10 a key capsid maturation step and also is important to viral RNA encapsidation [8,10]. Two structural
11 proteins VP1 and VP4 have been used for molecular epidemiological investigation and EV71
12 genotyping. Based on these studies, EV71 is currently classified into 3 genotypes, A, B and C and
13 genotypes B and C are further divided into B1-B5 and C1-C5 sub-genotypes [11,12]. Recent
14 epidemics in Malaysia, Singapore, Taiwan, and Thailand were caused by B5 isolates; the virus strain
15 that circulated in mainland China was C4 [12,13]. Therefore, an effective EV71 vaccine should elicit
16 strong cross-neutralizing antibody responses against different genotypes of EV71 in young children.
17 Two different membrane proteins, human P-selectin glycoprotein ligand-1 (PSGL-1) [14] and human
18 scavenger receptor class B, member 2 (SCARB2) [15] have been identified as cellular receptors for
19 EV71. Transgenic mice carrying these genes are being engineered and should be useful for HFMD
20 vaccine development.

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The heat-inactivated EV71 virion produced from Vero cell grown in serum-containing culture media has been shown to elicit more effective immune responses than those obtained from the recombinant VP1 protein or DNA vector vaccines in mice [4-6,16-18]. In the present study, we describe a scalable and reliable manufacturing process for a chemically-inactivated EV71 vaccine candidate that was capable of eliciting cross-neutralizing antibody responses in different animal

immunogenicity studies. Our present findings provide valuable information for a serum-free,
cell-based, heat-inactivated EV71 vaccine candidate going for human phase I clinical trials.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Materials and Methods

Ethics Statement

All experiments were conducted in accordance with NHRI Laboratory Animal Center guidelines, and approved by the NHRI Institutional Animal Care and Use Committee (Approval No. NHRI-IACUC-098033-A & NHRI-IACUC-099053-A).

Animal welfare and steps taken to ameliorate suffering

There were five well-trained veterinarians in Animal Health Research Institute of Taiwan (AHRI) to take care of total 15 monkeys. Monkey immunogenicity study was performed according to study protocol NHRI-IACUC-099053-A. All juvenile monkeys (macaques) were kept in a secured specific pathogens free (SPF) room with locked double-doors and security camera to ensure no animal escape or irrelevant person entry. Individual monkey was housing in a double-door, squeeze-back cage (62 x 62 x 72 cm), with toys to enrich the environment. Monkeys can contact each other in vision but not physical. Monkeys were fed with fresh local fruits twice a day. Monkeys received the routine check up (X-ray, stool exam, and serological tests). The related record (critical blood chemistry (CBC) data, feeding record, and body weight) would be kept for 10 years. All monkeys were chemically restrained with Zoletil (1.4-4.5 mg/Kg) before immunization or bleeding. The vital sign was monitored by breath and heart beating. In addition, animal would be euthanasia and removed from the study if one of the following signs appears: (1) unable to eat or drink; (2) unable to relieve a severe pain even receiving a medical treatment by a certificated veterinarian; (3) a high-risk pathogen infection. Normally monkeys were immunized intramuscularly (leg) with the alum-adsorbed inactivated EV71 vaccine candidate; and they were boosted twice with the same dose three weeks interval after priming. Immunized monkeys were bled three weeks after the final boost, and 10 mL of blood was collected for detecting specific IgG antibody titer and neutralizing antibody

1 titer. After blood samples collections, monkeys were placed back into original cages for recovery.
2 Usually, 15~20 minutes was needed and veterinarian monitored them. If an animal appeared to be in
3 poor condition, an adequate medical treatment or environment improvement would be used to relieve
4 the pain or distress. If the condition of an animal is out of control or is moribund, it may be
5 euthanized by Pentobarbital (100 mg/Kg; iv injection) after a certificated veterinarian's review. After
6 the study was completed, monkeys were still kept in AHRI with the same housing conditions. The
7 health condition of monkeys will be checked every 3-6 months with CBC examination and body
8 weight.
9
10
11
12
13
14
15
16
17
18
19
20
21

22 **Cells and virus**

23
24 Master and working Vero cell and virus (E59 strain) seed banks were established following
25 cGMP guidelines, characterized to fulfill the requirements for the manufacture of biological products
26 by BioReliance (UK), and reported in our previous study [19].
27
28
29
30
31
32
33

34 **Medium selection in 75 cm² T-flasks**

35
36 The serum-containing (SC) medium contained basal medium DMEM purchased from
37 Invitrogen (UK) and 5% fetal bovine serum (FBS) purchased from Moregate Biotech (Australia).
38 Plus Vero and HyQ medium were purchased from Cescio Bioengineering Co. (Taiwan) and Hyclone
39 (USA), respectively. VP-SFM and ExCell were supplied by Invitrogen (UK), and supplemented with
40 4 mM L-glutamine before use. Each 75 cm² T-flask was inoculated with approximately 1.0×10^6
41 cells and grown for 3 days in 20 mL medium. Every 24 hours, cell counts were determined by
42 detaching cells in each T-flask using 4 mL of Trypsin-EDTA solution purchased from Invitrogen
43 (UK). At each time point, cell counts were performed in triplicate.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

59 **Pilot Scale purification of EV71 virus using liquid chromatography**

1 EV71 virus stock was produced using the roller bottle technology, and purified by an AKTA
2 Pilot liquid chromatography system purchased from GE Healthcare (USA) equipped with Sepharose
3 Fast Flow 6 gel, and reported in our previous studies [10,19].
4
5
6
7
8

9 **SDS-PAGE analysis and Western blotting**

10
11 SDS-PAGE and Western blot analyses of the purified EV71 vaccine bulk were carried out
12 according to previously-reported protocols [10].
13
14
15
16
17
18

19 **Animal immunogenicity studies**

20
21 Mouse immunogenicity studies were conducted according to previously-reported protocols [10].
22
23 In parallel, rabbits, macaque monkeys and rats were immunized IM with 5-20 µg of protein
24 formulated with 1.5 mg of alum per dose. Sera were collected two weeks after each immunization
25 and used for immunological analysis.
26
27
28
29
30
31
32
33

34 **Virus neutralizing assay**

35
36 Virus neutralization titer of each sample was determined using TCID₅₀ assay according to the
37 previously-reported protocols [10,20].
38
39
40
41
42
43
44

45 **Enzyme-Linked Immunosorbent Assay (ELISA)**

46
47 The VP2 epitope-specific quantitative ELISA was carried out according to previously-reported
48 protocols [21]. The reactivity of the antibody to synthetic peptide VP1-43 [22] was analyzed by
49 peptide-ELISA according to the protocol previously reported by Panezutti *et al.*[23].
50
51
52
53
54
55
56

57 **Stability profiles of EV71 vaccine**

58
59 Eighty vials (3 mL each) containing either vaccine bulks (formalin-inactivated EV71 virion) or
60
61
62
63
64
65

1 vaccine products (20 µg of protein of vaccine bulk formulated with 3 mg of aluminum phosphate in
2 1 mL of PBS) were stored at 4 or 25°C for stability studies. The stability of vaccine bulk was
3
4 evaluated every 2 weeks for the first month and then every 3 months for up to 1 year using BCA
5 protein assay, VP2 Q-ELISA, SDS-PAGE and Western blot analysis, and mouse immunogenicity
6
7 study. The stability of the vaccine product was measured every month for the first 3 months and then
8
9 every 3 months for 18 months using BCA protein assay (to analyze the unabsorbed protein), sterility
10 tests and mouse immunogenicity studies.
11
12
13
14
15
16
17
18

19 **Residual DNA detection**

20
21 Residual cellular DNA was detected by the Threshold® System (Model 0200-0500) using the
22 Total DNA Assay Kit (MDC-R9004), both purchased from Molecular Devices Co. (USA). Five
23
24 hundred µL aliquots of Zero Calibrator, Positive Control, High Calibrator from the Total DNA
25 Assay Kit and the diluted samples (DNA content <400 pg/mL) were added into sterile DNA-free
26
27 tubes. The double-stranded DNA in the tubes was denatured by heating at 105°C for 15 minutes, and
28
29 the tubes were kept on ice until use. The standard solutions of single-stranded DNA into 0, 3.1, 6.3,
30
31 12.5, 25, 50, 100 and 200 pg per 0.5 mL were prepared using the High Calibrator. Labeling Reagent
32
33 from the Total DNA Assay Kit was mixed with DNA samples and standards, and the mixtures were
34
35 incubated at 37°C for 60 minutes. The filter block was pre-washed with the freshly-prepared
36
37 substrate solution according to manufacturer instructions. Each assay mixture was transferred to the
38
39 filter block, then filtered and washed. The concentration of DNA in the filter block was measured by
40
41 Threshold® System and calculated using the included Threshold® software.
42
43
44
45
46
47
48
49
50
51
52
53

54 **Residual cellular protein detection**

55
56 Vero cell protein-specific ELISA was used to measure the residual host protein content
57
58 remained in EV71 vaccine samples. The in-house standard of Vero cell lysate was prepared from
59
60
61
62
63
64
65

1 Vero cells grown in 200 mL SF medium in a roller bottle. The Vero cells were harvested and frozen
2 at -80°C overnight. The cells were frozen and thawed several times to generate cell lysate standard.
3
4 The total protein concentration of Vero cell lysate standard was determined by BCA protein assay.
5
6 One hundred micrograms of Vero cell lysate was mixed with the complete Freund's adjuvant (CFA)
7
8 and used to immunize rabbits 3 times for hyper-immune anti-Vero cell protein sera production. The
9
10 quality and titer of rabbit anti-Vero cell protein sera were analyzed using Western blot. The Vero cell
11
12 lysate standard was diluted into 0.15265, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg of protein/mL to
13
14 generate the standard curve. One hundred mL of the diluted samples in the coating buffer were
15
16 transferred into a 96-well microplate and tests were performed in duplicate. The microplate was
17
18 sealed and incubated overnight at room temperature, washed with 0.05% Tween-20 in phosphate
19
20 buffer saline (PBS), then blocked with 1% bovine serum albumin (BSA) in PBS at room temperature
21
22 for 2 hours. Purified rabbit anti-Vero cell lysate IgG as prepared above was 1:1000 diluted in 1%
23
24 BSA/PBS, then added into each well and incubated at room temperature for 2 hours. The microplate
25
26 was washed 3 times with 0.05% Tween-20 in PBS, a 1:5000 dilution of goat anti-rabbit IgG
27
28 conjugated to peroxidase (Chemicon USA) was added and incubated for 1 hour at room temperature.
29
30 After PBS, the microplate was washed again 6 times with 1% BSA/PBS, then peroxidase substrate
31
32 (KPL USA) was added and kept in the dark for 30 minutes. The stop solution (2N H₂SO₄) was added
33
34 into the microplate, and the absorbance of each well was read at 450 nm by a microplate reader
35
36 (Thermo Multiskan Spectrum USA) according to manufacturer instructions.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Results and Discussion

Evaluation and selection of serum-free medium

The performance of different media for Vero cell growth was screened and evaluated through the direct adaptation method [10,17,24]. The selection criteria were based on consistent cell growth performance over several passages. The cells were cultured in four different commercially-available SF media (Plus Vero, VP-SFM, HyQ and ExCell) and one SC medium (DMEM with 5% FBS supplement) in 75 cm² flasks over three passages after inoculation. As shown in Figure 1, the average cell counts in the SC medium, VP-SFM and Plus Vero were found to be higher than those found in the Excell and HyQ SF media (p<0.05). We further examined the consistency of VP-SFM and Plus Vero SF media for Vero cell growth, and found three batches of VP-SFM to have similar levels in cell growth profile, whereas the culture in Plus Vero showed greater fluctuations and sometimes lower cell growth rates (data not shown). The current results suggested that the VP-SFM could consistently promote the cell growth and virus yield (see below). Thus, the VP-SFM was selected as the SF medium and was subsequently used in all later experiments.

Optimization of EV71 virus yield

To evaluate the efficiency of E59/EV71 virus production in Vero cells grown in the VP-SFM medium, virus growth profile in T-flasks were done at four different multiplicities of infection (MOI): 0.01, 0.001, 0.0001 and 0.00001. As shown in Figure 2A, the virus titers in general decreased slightly during the first 2 days and then increased steadily after inoculation. The highest virus titer was 2×10^7 TCID₅₀/mL at 4 and 7 days post infection (DPI) for 0.01 and 0.00001 MOI, respectively. We also observed that increasing Vero cells ($2 - 2.5 \times 10^6$ cells) inoculation at the beginning of cell culture could generate a better virus yield (Figure 2A). To test whether temperature could influence virus growth and yield, the E59 strain was grown at various temperatures from 32 to 37°C. No

1 significant differences in virus growth profile or yield were observed (data not shown). Therefore,
2 0.00001 MOI and 37°C were selected and subsequently used in all later production runs.
3
4
5

6 7 **Pilot scale up-stream process development** 8

9
10 The virus growth profiles of three typical pilot scale production batches (200 x 200 mL roller
11 bottles in each run) are shown in Figure 2B. In contrast to the results obtained from T-flasks, the
12 virus titer was capable of reaching 10⁷ TCID₅₀ /mL at 3 DPI. The production kinetics of the E59
13 strain was similar when using 200 mL or 400 mL of culture medium (data not shown). EV71 virus
14 was harvested and collected from the culture supernatant of each bottle at 5 DPI, prior to the onset of
15 cytopathic effects. The potential cell debris was then removed by micro-filtration through a 0.65 µm
16 membrane. To monitor and optimize the up-stream process, culture supernatants collected from each
17 manufacturing run were assayed for their titers of infectious virus particles using the TCID₅₀ assay
18 and VP2 epitope contents by Q-ELISA as previously described [21]. The titers of infectious virus
19 particles in the supernatants harvested from three cGMP lots were found to be 11.70, 6.31, and 10.5
20 × 10⁶ TCID₅₀ units per mL for Lot #1, 2, and 3, respectively (Table 1). VP2 epitope contents were
21 measured by Q-ELISA and found to be 11.9, 7.73, and 8.1 units of VP2 per mL in Lot #1, 2, and 3,
22 respectively. The VP2 epitope contents were at least 3 folds higher than those obtained from virus
23 produced in serum-containing medium [19]. The reason is unclear to us at this moment.
24
25

26
27 The VP2 epitope content per 10⁶ TCID₅₀ infective units were calculated to be 1.02 (11.9/11.7),
28 1.23 (7.73/6.31), and 0.77(8.1/10.5) for Lot #1, 2, and 3, respectively. These results are consistent
29 with our previous small-scale research studies [21] that have shown the VP2 epitope content and the
30 titer of infectious viral particles to be uncorrelated. In contrast, the ratio between VP2 content and
31 total protein in the harvest shown in Table 1 was found to be relatively consistent in all three Lots
32 (0.008, 0.006, and 0.006 for Lot #1, 2, and 3, respectively). Together, both results suggest that EV71
33 viral antigens are consistently produced from Vero cells grown in the VP-SFM culture system, but
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

varying amounts of viral antigens are assembled to become infectious virus particles.

To facilitate downstream purification, the crude virus bulk was concentrated 20- to 40-fold using a 100 kDa cut-off diafiltration membrane in a tangential flow filter (TFF) cassette. As shown in Table 1, the TFF process was found to be efficient with high recoveries of viral antigens based on Q-ELISA units of VP2 (119%, 97%, and 104% for Lot #1, 2, and 3, respectively). The TFF process not only concentrated the viral antigens, but also removed significant amounts of cell proteins as the ratio between VP2 content and total protein as shown in Table 1 increased >40 fold (0.25/0.006 for Lot #3). However, Q-ELISA units of VP2 epitope per 10^6 TCID₅₀ infectious units were found to be 13.6 (531/38.9), 2.8 (249/87.1), and 1.5 (338/223) for Lots #1, 2, and 3, respectively. Again, the VP2 epitope content measured by Q-ELISA did not correlate well with TCID₅₀ values. These results suggest that the un-assembled VP2 antigens were not removed from the virus concentrate at the 100 kDa TFF step. These results may also explain why 300 kDa cut-off diafiltration membranes used in the TFF step were less effective in the recovery of VP2 content as determined by Q-ELISA.

Pilot scale downstream purification process

Three pilot-scale virus concentrates (~1 liter) were purified using the AKTA Pilot liquid chromatography system (Table 1). The EV71 virus was generally identified and located in fractions 3 to 8 as determined by SDS-PAGE, Western blot, and TCID₅₀. The EV71 virus fractions were pooled and concentrated using a 100 kDa TFF membrane. As shown in Table 1, ELISA units of VP2 epitope per 10^6 TCID₅₀ infectious units were found to be 4.87 (181.3/37.2), 4.15 (130.4/31.4), and 2.05 (214.4/104.7) for Lot #1, 2, and 3, respectively. These results suggest that the virus bulk pooled from multiple fractions may still contain various amounts of defective and infectious EV71 particles. As shown in Table 1, the ELISA units of VP2 epitope per μ g of protein was found to be 2.43, 2.02, and 3.46 for Lots #1, 2, and 3, respectively. These results are close to those obtained from the 3 previously reported research Lots (3.8, 5.3 and 3.4) [21]. Furthermore, the overall recovery yield

1 based on VP2 content determined by ELISA varied (27.9, 37.1, and 57.0% for Lots #1, 2, and 3,
2 respectively) in these three pilot runs. The gel-filtration chromatography removed >95% (>1300
3 decreased to 62 µg/mL of total protein for Lot #3) of potential contaminants. The residual host cell
4 proteins within the virus bulks was determined using Vero cell-specific ELISA as described in the
5 Materials and Methods and found to be 2.72, 2.61, and 2.38 µg/mL for Lots #1, 2, and 3,
6 respectively. The current results indicate that 5% (2.61/50.3 of Lot #2) of total protein are residual
7 Vero cell proteins within the virus bulks. As a result, there is still room for improvement in the
8 chromatographic purification process.

9
10
11
12
13
14
15
16
17
18
19 Two hundred mL of formalin-inactivated chromatographically-purified viral stock (64 µg/mL)
20 was further purified using sucrose gradient ultracentrifugation as previously described [10]. Two
21 kinds of EV71 virus particles were detected by TCID₅₀ assay and Western blot analysis, the defective
22 and infective particles were found in the fractions containing 25-28% and 35-38% sucrose,
23 respectively (data not shown). When protein concentrations of both EV71 particle pooled fractions
24 were measured by BCA method, it was found that there were 3 times more defective particles (52
25 µg/mL) than infectious particles (15 µg/mL). Like in our previous report [10], the purified infectious
26 EV71 virus was shown to be consisted of all 4 structural proteins VP1, VP2, VP3 and VP4. In
27 contrast, in the defective viral particles VP0, VP1 and VP3 protein bands were found to be the major
28 components as shown in the SDS-PAGE and Western blot analysis [10]. Although ultra-pure EV71
29 virus bulk could be obtained by combining the purification process of liquid chromatography with
30 sucrose gradient ultracentrifugation, the recovery yield was less than 20% of the
31 chromatographically-purified viral stock. Since the defective particle fractions are also immunogenic
32 and could elicit neutralizing antibody responses in both immunized mice and rabbits as previously
33 reported [10,19,21], it was therefore decided that the pilot-scale downstream purification would use
34 gel-filtration chromatography.

Chemical inactivation optimization

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

In previous reports [10,19,21,22,25], the purified EV71 virus bulk could be inactivated with formalin either at 4°C for weeks or 37°C for a few days, but these inactivation processes had not been validated for virus reversion. Therefore, the formalin-inactivation kinetic was performed at 4, 25, and 37°C. The results are shown in Figure 3, no infectivity was detected in the samples taken 18 and 72 hours after exposure to 0.025% (v/v) of formalin at 37 and 25°C, respectively. After 24 days, no infectious EV71 was observed in the samples taken from 4°C. Based on the current inactivation kinetic, the complete viral inactivation for 10¹² TCID₅₀ titer virus bulk would require 2.16, 12.6 and 31.64 days at 37, 25, and 4°C, respectively (Figure 3). After 0.22 µm sterile filtration, the total protein concentration measured by the BCA assay was found to have 20-30% loss of protein content during the inactivation and sterile filtration steps (Table 1). However, the Q-ELISA unit in the vaccine bulk was found to be similar to the value observed in the virus bulk before inactivation. These results suggest that formalin inactivation did not modify the VP2 epitope content as determined by VP2 Q-ELISA. In addition, the residual DNA in the EV71 vaccine bulk was determined according to the protocol described in the Materials and Methods section and found to be 16.67, 8.13, and 2.87 pg/mL for Lot #1, 2, and 3, respectively. These levels would pass the acceptance criteria for human vaccine (10 ng/dose) based on FDA guidelines.

Immunogenicity studies of EV71 vaccine candidates

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The quality of EV71 vaccine bulks (formalin-inactivated EV71 whole virions) was analyzed by SDS-PAGE and Western blots (Figure 4). After silver-staining SDS-PAGE gels, the dominant protein bands with molecular weight (MW) 28 and 38 kDa were observed in the vaccine bulks (Figure 4A, lanes 2 & 3). From our previous studies [10,19,21,22,25], protein bands with MW 38 and 28 kDa correspond to VP0/VP1 and VP2, respectively. Since the gel was loaded with the same amount of vaccine bulk based on protein concentration (2 µg per lane), it was suggested that Lot #1

1 contained more VP0/VP1 and VP2 antigens than Lot #2. This observation is consistent with the ratio
2 of VP2 epitope/total protein found in Lots #1 (3.74) and #2 (2.59). The vaccine bulks were further
3 analyzed by Western blot using two monoclonal antibodies (MAb) with different specificity:
4 MAB979 recognizes an epitope of VP2, while N1 reacts with VP1 [21,22,25] As shown in Figures
5 4B and C, both MAb recognized similar antigen patterns in both Lots #1 and 2. We observed similar
6 Western blot results from Lot #3 (data not shown). These results indicate that the antigen patterns of
7 EV71 vaccine bulks were produced consistently throughout the current manufacturing process.
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Mouse immunogenicity studies summarized in Table 2 revealed that the formalin-inactivated EV71 virions were highly potent in eliciting virus neutralization titer that were correlated with VP2 epitope units [10,19,21,22,25]. Although the neutralization titer was decreased (2- to 14-fold), sera from mice immunized twice with EV71 vaccine bulk were capable of cross-neutralizing other isolates from B4, B5 sub-genotype and C4 genotype (Table 2).

The results of other animal (rats, rabbits and macaques) immunogenicity studies are shown in Table 2. Sera from the immunized animals were found to have strong cross-neutralization titer against other B subgenotypes and C genotypes of EV71. Our current results are consistent with the conclusions reported by both Bek *et al.* and Dong *et al.*, [26,27]. They had produced formalin-inactivated EV71 vaccine candidates based on C4 genotype virus that could elicit cross-genotypes neutralizing antibody responses in mouse and non-human primate models [26,27]. They suggest that the common neutralization epitopes of EV71 virus are most likely conformational that could elicit strong cross-neutralizing antibody responses against different EV71 genotypes.

Stability profiles of vaccine bulks and formulated vaccine candidates

The stability profile of 2 different lots of EV71 vaccine bulks based on protein assay and VP2 Q-ELISA are summarized in Table 3. After 1 year of storage at either 4 or 25°C, there was no sign of protein loss in the vaccine bulk. VP2 epitope in both vaccine bulk lots remained relatively stable at

1 4°C, but there was trend of epitope loss after 1 and 3 months at 25°C storage for Lot #1 and 3,
2 respectively. Based on Western blot analyses using two different monoclonal antibodies N16 specific
3 for the N-terminal peptide of VP1 and MAB979 specific for VP2 shown in Figure 4B and C, there
4 was no EV71 VP1- or VP2-specific protein degradation (no protein fragments with MW below either
5 VP1 and/or VP2 were observed) in the vaccine bulks Lot #1 and 3 stored at 4°C for 12 months.
6
7 Mouse immunogenicity studies with both vaccine bulks stored at 4°C for 0, 1, 2 and 3 months (2 x 2
8
9 µg/dose immunization at 2 weeks apart) revealed that these samples were highly immunogenic and
10 elicited similar geometric mean titer (GMT) of virus neutralization against E59 vaccine strain
11 ranging from 200 to 600 (data not shown). No contamination was observed in all sterility tests.
12
13 Together, these stability profiles indicate that the EV71 vaccine bulks produced from the current
14 manufacturing process stored at 4°C for 1 year are sterile, stable, and immunogenic in mice.
15
16

17
18 The vaccine products were analyzed using a Hitachi H-7650 electron microscope according to
19 previously reported protocols [10], some free inactivated EV71 particles were observed and not
20 absorbed onto the alum (data not shown). When the kinetics of vaccine absorption to alum were
21 examined, >50% of protein in the EV71 vaccine product was absorbed within 1 hour after mixing the
22 vaccine bulk with the aluminum phosphate at room temperature. The current data from 3 and 6
23 months storage also confirm that the rate of alum absorption is more efficient at 25°C in both Lot #1
24 and 3 (Table 4). In addition, it seems that the virus neutralization titers elicited in mice immunized
25 with the EV71 vaccine product were correlated with the percentage of protein absorbed to alum,
26 particularly in Lot #3 (913 vs. 400 at 4°C and 850 vs. 335 at 25°C). The stability profile of the EV71
27 vaccine product is supported by no obvious losses of IgG and virus neutralization titers in mouse
28 immunogenicity studies. In the current 18-month stability program, the mouse immune responses
29 also reveal that the EV71 vaccine products from both lots are highly stable for long term storage at
30 4°C. Finally, no contamination was observed in sterility tests performed at 0, 3, 12 and 18 months.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Conclusion

Based the current results, the pilot scale manufacturing process of cell-based EV71 vaccine has been successfully developed, optimized, characterized, and quantified. In the up-stream process development, VP-SFM serum-free medium was identified to be the optimal medium for Vero cell growth and EV71 virus production. Gel filtration chromatography was found to be the most cost-effective for downstream purification, resulting in overall virus yields as high as 57% (Table 1). The formalin-inactivated virion vaccine candidate was found to be stable >18 months at 4°C. At microgram-levels, viral proteins formulated with alum adjuvant could induce strong virus-neutralizing antibody responses in mice, rats, rabbits, and non-human primates. These results provide valuable information supporting the current EV71 vaccine candidate going into human Phase 1 clinical trials.

Acknowledgements

This work was supported by a grant (No. 98A1-VCSP01-014) from the National Science Council (NSC) of Taiwan.

References

1. Ho, M, Chen ER, Hsu KH, Wu SJT, Chen KT, et al. (1999) The Taiwan Enterovirus Epidemic Working Group. An epidemic of enterovirus 71 infection in Taiwan. *N Engl J Med.* 341:929-935.
2. McMinn PC (2002). An overview of the evolution of enterovirus 71 and its clinical and public health significance. *FEMS Microbiol Rev* 26:91-107.
3. Xu J, Qian Y, Wang S, Serrano JMG, Li W, et al. (2010) An emerging infectious disease vaccine target in the Far East? *Vaccine* doi:10.1016/j.vaccine.2010.03.003.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
4. Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. *Expert Rev Vaccines* 9:149-156.
5. Solomon T, Lewthwarte P, Perera D, Cordosa MJ, McMinn P, Ooi MH. (2010) *Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet. Infect Dis.* 10:778-90.
6. Huang ML, Ho MS, Lee MS (2011) Enterovirus 71 vaccine: when will it be available? *J. Formos Med Assoc.* 110:425-27.
7. Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. *J Infect Dis* 129:304-9
8. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. *Vaccine* 26:1855-62.
9. Brown, BA, Pallansch MA (1995) Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. *Virus Res* 39:195-205.
10. Liu CC, Guo MS, Lin FHY, Hsiao KN, Chang KHW, et al. (2011) Purification and characterization of EV71 viral particles produced from Vero cell grown in a serum-free microcarrier bioreactor system. *PLoS ONE* doi:10.1371/journal.pone.0020005.
11. Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P et al. (2008) Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. *J. Clin. Microbiol* 46:3192-3200.
12. Chan YF, Sam IC, Abubakar SC (2010) Phylogenetic designation of EV71 genotypes and subgenotypes using complete genome sequences. *Infection, Genetics and Evolution* 10:404-12.
13. Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in Taiwan: Dynamics of genetic and antigenic evolution from 1998 to 2008. *J Clin Microbiol* 47:3653-3662.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
14. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. *Nature Med* 15:794-797.
15. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. *Nature Med* 15:798-801.
16. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS (2002) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. *Vaccine* 20: 895-904.
17. Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. *Vaccine* 25:19-24.
18. Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. *Genet Vaccines Ther* 5:6.
19. Chang JY, Chang CP, Tsaia HHP, Lee CD, Lian WC, et al. (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. *Vaccine* 30:703-711.
20. Reed LJ, Muench H (1938) A simple method of estimating 50 percent end-points. *Am J Hyg* 27:493-497.
21. Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, et al. (2011) Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process. *J Virol Methods*. doi:10.1016/j.jviromet.2011.06.001.
22. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of EV71. *Vaccine*; 29:4362-73.
23. Panzutti H, James O, Hansen EJ, Choi Y, Harkness RE, et al. (1993) Identification of surface-exposed B-cell epitopes recognized by *H. Influenzae* type b P1-specific monoclonal antibody. *Infect Immun* 61:1867-1872.
24. Wu SC., Liu CC, Lian WC (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. *Vaccine* 22:3858-64.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
25. Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, et al (2011) Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genotype B isolates. *J Virol Methods* 173:189-95.
 26. Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. *Vaccine* 29:4829-38.
 27. Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. *Vaccine* 29:6269-75.

Figure Legends

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. The growth profiles of Vero cell grown in serum-containing medium (SC) and different serum-free media (SF). Vero cells (2×10^5 cell/ml) was cultured in 75T-flask and counted for viable cell number every 24 hours (0, 24, 48, 72, 96, 120 and 144 hours). The conditions for cell culture were described in the Materials and Methods section.

Figure 2. The optimization of the up-stream process for EV71 virus production. (A) The T-flask was seeded with either $1.0 \sim 1.5 \times 10^6$ or $2.0 \sim 2.5 \times 10^6$ Vero cells, then after 2-3 days the cells were infected by the different ratio of E59/EV71 virus. The effects of different M.O.I were detected in the kinetic profile of virus produced from Vero cell grown in the VP-SFM medium. (B) The consistency of 3 Lots of EV71 virus production in the roller bottles. Virus titer was detected every day by TCID₅₀ for 5 days.

Figure 3. The temperature effect in the kinetic of formalin-inactivation of EV71 virus. Purified E59/EV71 was inactivated by 0.025% (v/v) formalin at different temperature and the residual of virus infectivity was detected by plaque assay performed triplicate at different time points.

Figure 4. The stability profiles of different Lots of EV71 vaccine products stored at 4 °C for various time and analyzed by SDS-PAGE (Panel A) and Western blot (Panel B & C). Lane M is MW Markers; lane 1 is EV71 vaccine product produced from serum-containing medium and stored at 4 °C for 26 months; lanes 2 and 3 are EV71 vaccine products derived from Lot #1 and 2 and stored at 4 °C for 13 and 4 months, respectively. Monoclonal antibody used in the Panels B and C are MAB979 specific for VP2 and N16 specific for VP1, respectively.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Summary of in-process characterizations of EV71 vaccine bulk produced from serum-free medium.

Lot #	Process step	Total volume (L)	TCID ₅₀ ^a (x10 ⁶ /mL)	Total Protein ^b (µg/mL)	VP2 epitope ^c (Unit/mL)	Recovery ^d (%)	VP2 epitope/Total Protein (Unit/µg)
Lot #1	Harvest	41.0	11.7	1459.8 +/- 5.5	11.9 +/- 0.8	100	0.008
	Dif/Con ^e	1.10	38.9	825.6 +/- 9.5	531.0 +/- 14.5	119.7	0.64
	LC ^f	0.75	37.2	74.5 +/- 0.8	181.3 +/-16.7	27.9	2.43
	Formalin Inactivated	0.75		53.0 +/- 1.5	198.4 +/- 21.3	30.5	3.74
Lot #2	Harvest	40.0	6.31	1373.1 +/- 29.1	7.73 +/- 0.23	100	0.006
	Dif/Con	1.20	87.1	1351.7 +/- 13.6	249.0 +/- 12.47	96.6	0.18
	LC	0.88	31.4	64.4 +/- 0.89	130.4 +/- 9.07	37.1	2.02
	Formalin Inactivated	0.80		50.3 +/- 1.27	130.4 +/- 6.7	33.9	2.59
Lot #3	Harvest	40.7	10.5	1318.7 +/- 27.6	8.1 +/- 0.31	100	0.006
	Dif/Con	1.00	223.9	1333.4 +/- 32.3	338 +/- 17.5	103.9	0.25
	LC	0.88	104.7	62.0 +/- 0.74	214.4 +/-25.1	57.0	3.46
	Formalin Inactivated	0.85		60.7 +/- 2.82	167.0 +/- 7.43	43.1	2.75

ND: not determined.

^aTCID₅₀ is the median tissue culture infective dose of EV71 that produces pathological cytopathic effects (CPE) in 50% of inoculated cell cultures.

^bTotal protein concentration was determined by the BCA protein assay.

^cVP2-specific epitope content was determined by Q-ELISA [19].

^dRecovery was calculated using the total VP2 epitope content at each step divided by the total VP2 epitope at the harvest stage.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

^ediafiltration/ concentration step.

^fgel-filtration chromatography purification.

Table 2. Immunogenicity studies of EV71 vaccine bulks

Animal Model	Vaccine Lot #	Total proteins (µg/dose)	VP2 Q-ELISA unit/dose	IgG Titer (GMT)	TCID ₅₀ Neutralization titer (GMT)			
					B4/E59	B4/S0302	C4	B5
BALB/c Mouse	1	2	7.5	4,525	443	256	32	128
	2	2	5.2	2,934	233	ND*	64	256
	3	2	5.5	2,851	234	ND	ND	ND
Rat	2	10	26	12,800	654	ND	64	128
Rabbit-G1	1	5	18.8	>32,000	13,573	5,677	8,192	5,677
Rabbit-G2	1	10	37.6	>32,000	13,318	ND	13,520	16,384
Rabbit-G3	2	5	13	>32,000	17,093	ND	ND	ND
Rabbit-G4	2	10	26	>32,000	19,308	ND	ND	ND
Macaque	1	10	37.6	>32,000	5,623	ND	5,623	3,169
Macaque	3	5	13.8	25,600	3,169	ND	ND	ND
Macaque	3	10	27.6	25,600	8,912	ND	ND	ND

Eight mice per group and 5 rats per group were immunized twice with formalin-inactivated EV71 virion formulated with alum. Two rabbits per group and individual macaques were immunized three times with formalin-inactivated EV71 virion formulated with alum. The immunization protocol, IgG tier and virus neutralization assay are described in the Materials and Methods section.

* not done.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3. Stability profiles of EV71 vaccine bulks.

Time	Vaccine Bulk Lot #1 stored at different temperature				Vaccine bulk Lot #3 stored at different temperature			
	Total protein (mcg/mL)		VP2 epitope (Unit/mL)		Total protein (mcg/mL)		VP2 epitope (Unit/mL)	
	4°C	25°C	4°C	25°C	4°C	25°C	4°C	25°C
Initial	57.01	57.01	198.35	227.54	48.76	48.76	199.80	199.80
2 weeks	ND	60.73	ND	181.65	ND	50.86	ND	209.55
1 month	58.75	58.25	198.29	150.59	47.74	48.46	206.02	191.36
3 month	58.55	60.50	168.69	156.76	52.59	51.31	192.48	170.48
6 month	57.70	59.27	188.05	137.49	52.19	53.76	190.29	168.52
9 month	58.75	ND	180.35	ND	51.54	51.07	218.64	145.36
12 month	47.76	ND	174.03	ND	46.18	ND	214.39	ND

The total protein and VP2 antigen content in the vaccine bulks were determined by BCA method and VP2 Q-ELISA, respectively.

Table 4. Stability profiles of EV71 vaccine products (70 µg of formalin-inactivated EV71 virion formulated with 9 mg of aluminum phosphate in 3 mL of PBS).

Time		Lot #1			Lot #3		
		Unabsorbed Protein (µg/mL)	IgG (GMT ± SE)	Neutralization Titer (GMT ± SE)	Unabsorbed Protein (µg/mL)	IgG (GMT ± SE)	Neutralization Titer (GMT ± SE)
Initial		23.3	4525 ± 705	443 ± 279	23.3	2934 ± 705	233 ± 99
1 month		6.57 ± 0.16	1037 ± 316	153 ± 52	8.56 ± 0.30	1131 ± 176	265 ± 27
2 month		7.69 ± 0.35	2075 ± 353	105 ± 89	9.77 ± 0.04	1903 ± 262	246 ± 14
3 month	4°C	7.15 ± 2.58	1600 ± 330	120 ± 58	9.34 ± 1.19	2263 ± 302	400 ± 88
	25°C	5.00 ± 0.01	2075 ± 353	269 ± 110	6.46 ± 0.12	3200 ± 761	913 ± 125
6 month	4°C	8.25 ± 0.22	1345 ± 280	79 ± 29	9.88 ± 0.11	2691 ± 262	335 ± 83
	25°C	5.36 ± 0.23	1745 ± 300	262 ± 122	7.07 ± 0.37	3200 ± 659	850 ± 122
9 month		5.59 ± 0.08	2986 ± 413	534 ± 90	8.00 ± 0.19	3200 ± 0	1089 ± 187
12 month		5.87 ± 0.06	4222 ± 523	301 ± 86	8.00 ± 0.20	3676 ± 427	349 ± 85
18 month		7.03 ± 0.51	1393 ± 227	534 ± 77	8.82 ± 0.83	2599 ± 244	643 ± 97

Eight mice per group were immunized twice with 0.2 mL of EV71 vaccine products Lot #1 and 3 that were stored in stability study chambers with different pre-set temperatures. The immunization protocol, IgG tier and virus neutralization assay are described in the Materials and Methods section.

Figure 1




Figure 2A




Figure 2B




Figure 3







Figure 4



A



B



C

Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates

Ai-Hsiang Chou^{a,1}, Chia-Chyi Liu^{a,1}, Cheng-Peng Chang^a, Meng-Shin Guo^a, Shih-Yang Hsieh^a, Wen-Hsueh Yang^a, Hsin-Ju Chao^a, Chien-Long Wu^a, Ju-Lan Huang^a, Min-Shi Lee^a, Alan Yung-Chi Hu^a, Sue-Chen Lin^a, Yu-Yun Huang^a, Mei-Hua Hu^a, Yen-Hung Chow^a, Jen-Ron Chiang^b, Jui-Yuan Chang^a, and Pele Chong^{a,c,*}

^aVaccine R&D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County, Taiwan 350. ^bVaccine Center, Taiwan Centers for Diseases Control, Taipei, Taiwan. ^cGraduate Institute of Immunology, China Medical University, Taichung, Taiwan.

¹These authors equally contributed to this work.

*Corresponding authors: Pele Chong, Vaccine R&D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County, Taiwan 350. 886-37-246 166, ext 37800; Email: pelechong@nhri.org.tw (PC).

Running title: Cell-based EV71 vaccine candidate

Key Words: Hand-Foot-Mouth Diseases, Enterovirus 71, inactivated whole virion vaccine, serum-free culture technology, cross-neutralizing antibody

Author Contributions:

Conceived and designed the experiments: J-YC, Y-CH, C-CL, S-YH, A-HC, PC.

Performed the experiments: J-YC, C-PC, C-CL, M-SG, C-YC, A-HC, S-CL, H-JC, C-LW, Y-YH, W-HY, J-LH, S-YH.

Analyzed the data: J-YC, M-SG, C-CL, S-YH, Y-CH, H-JC, M-SL, Y-HC, J-LH, A-HC, PC.

Contributed reagents/materials/analysis tools: J-RC, J-YC, M-SG, C-CL, Y-HC, C-LW, A-HC, M-SL, J-LH, S-YH

Wrote the paper: A-HC, C-CL, PC.

Abstract

Background: Enterovirus 71 (EV71) has caused several epidemics of hand, foot and mouth diseases (HFMD) in Asia and now is being recognized as an important neurotropic virus. Effective medications and prophylactic vaccine against EV71 infection are urgently needed. Based on the success of inactivated poliovirus vaccine, a prototype chemically inactivated EV71 vaccine candidate has been developed and currently in human phase 1 clinical trial.

Principal Finding: In this report, we present the development of a serum-free cell-based EV71 vaccine. The optimization at each step of the manufacturing process was investigated, characterized and quantified. In the up-stream process development, different commercially-available cell culture media either containing serum or serum-free was screened for cell growth and virus yield using the roller-bottle technology. VP-SFM serum-free medium was selected based on the Vero cell growth profile and EV71 virus production. After the up-stream processes (virus harvest, diafiltration and concentration), a combination of gel-filtration liquid chromatography and/or sucrose-gradient ultracentrifugation down-stream purification processes were investigated at a pilot scale of 40 liters each. Although the combination of chromatography and sucrose-gradient ultracentrifugation produced extremely pure EV71 infectious virus particles, the overall yield of vaccine was 7-10% as determined by a VP2-based quantitative ELISA. Using chromatography as the downstream purification, the virus yield was 30-43%. To retain the integrity of virus neutralization epitopes and the stability of the vaccine product, the best virus inactivation was found to be 0.025% formalin-treatment at 37°C for 3 to 6 days. Furthermore, the formalin-inactivated virion vaccine candidate was found to be stable for >18 months at 4°C and a microgram of viral proteins formulated with alum adjuvant could induce strong virus-neutralizing antibody responses in mice, rats, rabbits, and non-human primates.

Conclusion: These results provide valuable information supporting the current cell-based serum-free EV71 vaccine candidate going into human Phase I clinical trials.

Introduction

Enterovirus 71 (EV71) infections have recently emerged in Asia as a serious cause of hand, foot and mouth disease (HFMD) in children that can lead to severe neurological complications and death [1-4]. Different types of vaccines against EV71 infection are being developed [4-6] and promising candidates are being evaluated in human Phase 1 clinical trials [6]. EV71 is a non-enveloped RNA virus of the family *Picornaviridae*, first identified in 1969 in the United States [7]. The EV71 virus particle contains a single molecule of plus sense ssRNA (7.5-8.5 kb). The complete nucleotide sequence of the EV71 prototype strain BrCr has been determined and contains four structural proteins: VP1, VP2, VP3 and VP4 [8,9]. **The cleavage of VP0 into VP2 and VP4 has been shown as a key capsid maturation step and also is important to viral RNA encapsidation [8,10].** Two structural proteins VP1 and VP4 have been used for molecular epidemiological investigation and EV71 genotyping. Based on these studies, EV71 is currently classified into 3 genotypes, A, B and C and genotypes B and C are further divided into B1-B5 and C1-C5 sub-genotypes [11,12]. Recent epidemics in Malaysia, Singapore, Taiwan, and Thailand were caused by B5 isolates; the virus strain that circulated in mainland China was C4 [12,13]. Therefore, an effective EV71 vaccine should elicit strong cross-neutralizing antibody responses against different genotypes of EV71 in young children. **Two different membrane proteins, human P-selectin glycoprotein ligand-1 (PSGL-1) [14] and human scavenger receptor class B, member 2 (SCARB2) [15] have been identified as cellular receptors for EV71. Transgenic mice carrying these genes are being engineered and should be useful for HFMD vaccine development.**

The heat-inactivated EV71 virion produced from Vero cell grown in serum-containing culture media has been shown to elicit more effective immune responses than those obtained from the recombinant VP1 protein or DNA vector vaccines in mice [4-6,16-18]. In the present study, we describe a scalable and reliable manufacturing process for a chemically-inactivated EV71 vaccine candidate that was capable of eliciting cross-neutralizing antibody responses in different animal

immunogenicity studies. Our present findings provide valuable information for a serum-free, cell-based, heat-inactivated EV71 vaccine candidate going for human phase I clinical trials.

Materials and Methods

Ethics Statement

All experiments were conducted in accordance with NHRI Laboratory Animal Center guidelines, and approved by the NHRI Institutional Animal Care and Use Committee (Approval No. NHRI-IACUC-098033-A & NHRI-IACUC-099053-A).

Animal welfare and steps taken to ameliorate suffering

There were five well-trained veterinarians in Animal Health Research Institute of Taiwan (AHRI) to take care of total 15 monkeys. Monkey immunogenicity study was performed according to study protocol NHRI-IACUC-099053-A. All juvenile monkeys (macaques) were kept in a secured specific pathogens free (SPF) room with locked double-doors and security camera to ensure no animal escape or irrelevant person entry. Individual monkey was housing in a double-door, squeeze-back cage (62 x 62 x 72 cm), with toys to enrich the environment. Monkeys can contact each other in vision but not physical. Monkeys were fed with fresh local fruits twice a day. Monkeys received the routine check up (X-ray, stool exam, and serological tests). The related record (critical blood chemistry (CBC) data, feeding record, and body weight) would be kept for 10 years. All monkeys were chemically restrained with Zoletil (1.4-4.5 mg/Kg) before immunization or bleeding. The vital sign was monitored by breath and heart beating. In addition, animal would be euthanasia and removed from the study if one of the following signs appears: (1) unable to eat or drink; (2) unable to relieve a severe pain even receiving a medical treatment by a certificated veterinarian; (3) a high-risk pathogen infection. Normally monkeys were immunized intramuscularly (leg) with the alum-adsorbed inactivated EV71 vaccine candidate; and they were boosted twice with the same dose three weeks interval after priming. Immunized monkeys were bled three weeks after the final boost, and 10 mL of blood was collected for detecting specific IgG antibody titer and neutralizing antibody

titer. After blood samples collections, monkeys were placed back into original cages for recovery. Usually, 15~20 minutes was needed and veterinarian monitored them. If an animal appeared to be in poor condition, an adequate medical treatment or environment improvement would be used to relieve the pain or distress. If the condition of an animal is out of control or is moribund, it may be euthanized by Pentobarbital (100 mg/Kg; iv injection) after a certificated veterinarian's review. After the study was completed, monkeys were still kept in AHRI with the same housing conditions. The health condition of monkeys will be checked every 3-6 months with CBC examination and body weight.

Cells and virus

Master and working Vero cell and virus (E59 strain) seed banks were established following cGMP guidelines, characterized to fulfill the requirements for the manufacture of biological products by BioReliance (UK), and reported in our previous study [19].

Medium selection in 75 cm² T-flasks

The serum-containing (SC) medium contained basal medium DMEM purchased from Invitrogen (UK) and 5% fetal bovine serum (FBS) purchased from Moregate Biotech (Australia). Plus Vero and HyQ medium were purchased from Cescio Bioengineering Co. (Taiwan) and Hyclone (USA), respectively. VP-SFM and ExCell were supplied by Invitrogen (UK), and supplemented with 4 mM L-glutamine before use. Each 75 cm² T-flask was inoculated with approximately 1.0×10^6 cells and grown for 3 days in 20 mL medium. Every 24 hours, cell counts were determined by detaching cells in each T-flask using 4 mL of Trypsin-EDTA solution purchased from Invitrogen (UK). At each time point, cell counts were performed in triplicate.

Pilot Scale purification of EV71 virus using liquid chromatography

EV71 virus stock was produced using the roller bottle technology, and purified by an AKTA Pilot liquid chromatography system purchased from GE Healthcare (USA) equipped with Sepharose Fast Flow 6 gel, and reported in our previous studies [10,19].

SDS-PAGE analysis and Western blotting

SDS-PAGE and Western blot analyses of the purified EV71 vaccine bulk were carried out according to previously-reported protocols [10].

Animal immunogenicity studies

Mouse immunogenicity studies were conducted according to previously-reported protocols [10]. In parallel, rabbits, macaque monkeys and rats were immunized IM with 5-20 µg of protein formulated with 1.5 mg of alum per dose. Sera were collected two weeks after each immunization and used for immunological analysis.

Virus neutralizing assay

Virus neutralization titer of each sample was determined using TCID₅₀ assay according to the previously-reported protocols [10,20].

Enzyme-Linked Immunosorbent Assay (ELISA)

The VP2 epitope-specific quantitative ELISA was carried out according to previously-reported protocols [21]. The reactivity of the antibody to synthetic peptide VP1-43 [22] was analyzed by peptide-ELISA according to the protocol previously reported by Panezutti *et al.*[23].

Stability profiles of EV71 vaccine

Eighty vials (3 mL each) containing either vaccine bulks (formalin-inactivated EV71 virion) or

vaccine products (20 µg of protein of vaccine bulk formulated with 3 mg of aluminum phosphate in 1 mL of PBS) were stored at 4 or 25°C for stability studies. The stability of vaccine bulk was evaluated every 2 weeks for the first month and then every 3 months for up to 1 year using BCA protein assay, VP2 Q-ELISA, SDS-PAGE and Western blot analysis, and mouse immunogenicity study. The stability of the vaccine product was measured every month for the first 3 months and then every 3 months for 18 months using BCA protein assay (to analyze the unabsorbed protein), sterility tests and mouse immunogenicity studies.

Residual DNA detection

Residual cellular DNA was detected by the Threshold® System (Model 0200-0500) using the Total DNA Assay Kit (MDC-R9004), both purchased from Molecular Devices Co. (USA). Five hundred µL aliquots of Zero Calibrator, Positive Control, High Calibrator from the Total DNA Assay Kit and the diluted samples (DNA content <400 pg/mL) were added into sterile DNA-free tubes. The double-stranded DNA in the tubes was denatured by heating at 105°C for 15 minutes, and the tubes were kept on ice until use. The standard solutions of single-stranded DNA into 0, 3.1, 6.3, 12.5, 25, 50, 100 and 200 pg per 0.5 mL were prepared using the High Calibrator. Labeling Reagent from the Total DNA Assay Kit was mixed with DNA samples and standards, and the mixtures were incubated at 37°C for 60 minutes. The filter block was pre-washed with the freshly-prepared substrate solution according to manufacturer instructions. Each assay mixture was transferred to the filter block, then filtered and washed. The concentration of DNA in the filter block was measured by Threshold® System and calculated using the included Threshold® software.

Residual cellular protein detection

Vero cell protein-specific ELISA was used to measure the residual host protein content remained in EV71 vaccine samples. The in-house standard of Vero cell lysate was prepared from

Vero cells grown in 200 mL SF medium in a roller bottle. The Vero cells were harvested and frozen at -80°C overnight. The cells were frozen and thawed several times to generate cell lysate standard. The total protein concentration of Vero cell lysate standard was determined by BCA protein assay. One hundred micrograms of Vero cell lysate was mixed with the complete Freund's adjuvant (CFA) and used to immunize rabbits 3 times for hyper-immune anti-Vero cell protein sera production. The quality and titer of rabbit anti-Vero cell protein sera were analyzed using Western blot. The Vero cell lysate standard was diluted into 0.15265, 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg of protein/mL to generate the standard curve. One hundred mL of the diluted samples in the coating buffer were transferred into a 96-well microplate and tests were performed in duplicate. The microplate was sealed and incubated overnight at room temperature, washed with 0.05% Tween-20 in phosphate buffer saline (PBS), then blocked with 1% bovine serum albumin (BSA) in PBS at room temperature for 2 hours. Purified rabbit anti-Vero cell lysate IgG as prepared above was 1:1000 diluted in 1% BSA/PBS, then added into each well and incubated at room temperature for 2 hours. The microplate was washed 3 times with 0.05% Tween-20 in PBS, a 1:5000 dilution of goat anti-rabbit IgG conjugated to peroxidase (Chemicon USA) was added and incubated for 1 hour at room temperature. After PBS, the microplate was washed again 6 times with 1% BSA/PBS, then peroxidase substrate (KPL USA) was added and kept in the dark for 30 minutes. The stop solution (2N H₂SO₄) was added into the microplate, and the absorbance of each well was read at 450 nm by a microplate reader (Thermo Multiskan Spectrum USA) according to manufacturer instructions.

Results and Discussion

Evaluation and selection of serum-free medium

The performance of different media for Vero cell growth was screened and evaluated through the direct adaptation method [10,17,24]. The selection criteria were based on consistent cell growth performance over several passages. The cells were cultured in four different commercially-available SF media (Plus Vero, VP-SFM, HyQ and ExCell) and one SC medium (DMEM with 5% FBS supplement) in 75 cm² flasks over three passages after inoculation. As shown in Figure 1, the average cell counts in the SC medium, VP-SFM and Plus Vero were found to be higher than those found in the Excell and HyQ SF media ($p < 0.05$). We further examined the consistency of VP-SFM and Plus Vero SF media for Vero cell growth, and found three batches of VP-SFM to have similar levels in cell growth profile, whereas the culture in Plus Vero showed greater fluctuations and sometimes lower cell growth rates (data not shown). The current results suggested that the VP-SFM could consistently promote the cell growth and virus yield (see below). Thus, the VP-SFM was selected as the SF medium and was subsequently used in all later experiments.

Optimization of EV71 virus yield

To evaluate the efficiency of E59/EV71 virus production in Vero cells grown in the VP-SFM medium, virus growth profile in T-flasks were done at four different multiplicities of infection (MOI): 0.01, 0.001, 0.0001 and 0.00001. As shown in Figure 2A, the virus titers in general decreased slightly during the first 2 days and then increased steadily after inoculation. The highest virus titer was 2×10^7 TCID₅₀/mL at 4 and 7 days post infection (DPI) for 0.01 and 0.00001 MOI, respectively. We also observed that increasing Vero cells ($2 - 2.5 \times 10^6$ cells) inoculation at the beginning of cell culture could generate a better virus yield (Figure 2A). To test whether temperature could influence virus growth and yield, the E59 strain was grown at various temperatures from 32 to 37°C. No

significant differences in virus growth profile or yield were observed (data not shown). Therefore, 0.00001 MOI and 37°C were selected and subsequently used in all later production runs.

Pilot scale up-stream process development

The virus growth profiles of three typical pilot scale production batches (200 x 200 mL roller bottles in each run) are shown in Figure 2B. In contrast to the results obtained from T-flasks, the virus titer was capable of reaching 10^7 TCID₅₀ /mL at 3 DPI. The production kinetics of the E59 strain was similar when using 200 mL or 400 mL of culture medium (data not shown). EV71 virus was harvested and collected from the culture supernatant of each bottle at 5 DPI, prior to the onset of cytopathic effects. The potential cell debris was then removed by micro-filtration through a 0.65 µm membrane. To monitor and optimize the up-stream process, culture supernatants collected from each manufacturing run were assayed for their titers of infectious virus particles using the TCID₅₀ assay and VP2 epitope contents by Q-ELISA as previously described [21]. **The titers of infectious virus particles in the supernatants harvested from three cGMP lots were found to be 11.70, 6.31, and 10.5 × 10⁶ TCID₅₀ units per mL for Lot #1, 2, and 3, respectively (Table 1). VP2 epitope contents were measured by Q-ELISA and found to be 11.9, 7.73, and 8.1 units of VP2 per mL in Lot #1, 2, and 3, respectively.** The VP2 epitope contents were at least 3 folds higher than those obtained from virus produced in serum-containing medium [19]. The reason is unclear to us at this moment.

The VP2 epitope content per 10⁶ TCID₅₀ infective units were calculated to be 1.02 (11.9/11.7), 1.23 (7.73/6.31), and 0.77(8.1/10.5) for Lot #1, 2, and 3, respectively. These results are consistent with our previous small-scale research studies [21] that have shown the VP2 epitope content and the titer of infectious viral particles to be uncorrelated. In contrast, the ratio between VP2 content and total protein in the harvest shown in Table 1 was found to be relatively consistent in all three Lots (0.008, 0.006, and 0.006 for Lot #1, 2, and 3, respectively). Together, both results suggest that EV71 viral antigens are consistently produced from Vero cells grown in the VP-SFM culture system, but

varying amounts of viral antigens are assembled to become infectious virus particles.

To facilitate downstream purification, the crude virus bulk was concentrated 20- to 40-fold using a 100 kDa cut-off diafiltration membrane in a tangential flow filter (TFF) cassette. As shown in Table 1, the TFF process was found to be efficient with high recoveries of viral antigens based on Q-ELISA units of VP2 (119%, 97%, and 104% for Lot #1, 2, and 3, respectively). The TFF process not only concentrated the viral antigens, but also removed significant amounts of cell proteins as the ratio between VP2 content and total protein as shown in Table 1 increased >40 fold (0.25/0.006 for Lot #3). However, Q-ELISA units of VP2 epitope per 10^6 TCID₅₀ infectious units were found to be 13.6 (531/38.9), 2.8 (249/87.1), and 1.5 (338/223) for Lots #1, 2, and 3, respectively. Again, the VP2 epitope content measured by Q-ELISA did not correlate well with TCID₅₀ values. **These results suggest that the un-assembled VP2 antigens were not removed from the virus concentrate at the 100 kDa TFF step.** These results may also explain why 300 kDa cut-off diafiltration membranes used in the TFF step were less effective in the recovery of VP2 content as determined by Q-ELISA.

Pilot scale downstream purification process

Three pilot-scale virus concentrates (~1 liter) were purified using the AKTA Pilot liquid chromatography system (Table 1). The EV71 virus was generally identified and located in fractions 3 to 8 as determined by SDS-PAGE, Western blot, and TCID₅₀. The EV71 virus fractions were pooled and concentrated using a 100 kDa TFF membrane. As shown in Table 1, ELISA units of VP2 epitope per 10^6 TCID₅₀ infectious units were found to be 4.87 (181.3/37.2), 4.15 (130.4/31.4), and 2.05 (214.4/104.7) for Lot #1, 2, and 3, respectively. These results suggest that the virus bulk pooled from multiple fractions may still contain various amounts of defective and infectious EV71 particles. As shown in Table 1, the ELISA units of VP2 epitope per μ g of protein was found to be 2.43, 2.02, and 3.46 for Lots #1, 2, and 3, respectively. These results are close to those obtained from the 3 previously reported research Lots (3.8, 5.3 and 3.4) [21]. Furthermore, the overall recovery yield

based on VP2 content determined by ELISA varied (27.9, 37.1, and 57.0% for Lots #1, 2, and 3, respectively) in these three pilot runs. The gel-filtration chromatography removed >95% (>1300 decreased to 62 µg/mL of total protein for Lot #3) of potential contaminants. The residual host cell proteins within the virus bulks was determined using Vero cell-specific ELISA as described in the Materials and Methods and found to be 2.72, 2.61, and 2.38 µg/mL for Lots #1, 2, and 3, respectively. The current results indicate that 5% (2.61/50.3 of Lot #2) of total protein are residual Vero cell proteins within the virus bulks. As a result, there is still room for improvement in the chromatographic purification process.

Two hundred mL of formalin-inactivated chromatographically-purified viral stock (64 µg/mL) was further purified using sucrose gradient ultracentrifugation as previously described [10]. Two kinds of EV71 virus particles were detected by TCID₅₀ assay and Western blot analysis, the defective and infective particles were found in the fractions containing 25-28% and 35-38% sucrose, respectively (data not shown). When protein concentrations of both EV71 particle pooled fractions were measured by BCA method, it was found that there were 3 times more defective particles (52 µg/mL) than infectious particles (15 µg/mL). Like in our previous report [10], the purified infectious EV71 virus was shown to be consisted of all 4 structural proteins VP1, VP2, VP3 and VP4. In contrast, in the defective viral particles VP0, VP1 and VP3 protein bands were found to be the major components as shown in the SDS-PAGE and Western blot analysis [10]. Although ultra-pure EV71 virus bulk could be obtained by combining the purification process of liquid chromatography with sucrose gradient ultracentrifugation, the recovery yield was less than 20% of the chromatographically-purified viral stock. Since the defective particle fractions are also immunogenic and could elicit neutralizing antibody responses in both immunized mice and rabbits as previously reported [10,19,21], it was therefore decided that the pilot-scale downstream purification would use gel-filtration chromatography.

Chemical inactivation optimization

In previous reports [10,19,21,22,25], the purified EV71 virus bulk could be inactivated with formalin either at 4°C for weeks or 37°C for a few days, but these inactivation processes had not been validated for virus reversion. Therefore, the formalin-inactivation kinetic was performed at 4, 25, and 37°C. The results are shown in Figure 3, **no infectivity was detected** in the samples taken 18 and 72 hours after exposure to 0.025% (v/v) of formalin at 37 and 25°C, respectively. After 24 days, **no infectious EV71** was observed in the samples taken from 4°C. Based on the current inactivation kinetic, the complete viral inactivation for 10¹² TCID₅₀ titer virus bulk would require 2.16, **12.6** and 31.64 days at 37, 25, and 4°C, respectively (Figure 3). After 0.22 µm sterile filtration, the total protein concentration measured by the BCA assay was found to have 20-30% loss of protein content during the inactivation and sterile filtration steps (Table 1). However, the Q-ELISA unit in the vaccine bulk was found to be similar to the value observed in the virus bulk before inactivation. These results suggest that formalin inactivation did not modify the VP2 epitope content as determined by VP2 Q-ELISA. In addition, the residual DNA in the EV71 vaccine bulk was determined according to the protocol described in the Materials and Methods section and found to be 16.67, 8.13, and 2.87 pg/mL for Lot #1, 2, and 3, respectively. These levels would pass the acceptance criteria for human vaccine (10 ng/dose) based on FDA guidelines.

Immunogenicity studies of EV71 vaccine candidates

The quality of EV71 vaccine bulks (formalin-inactivated EV71 whole virions) was analyzed by SDS-PAGE and Western blots (Figure 4). After silver-staining SDS-PAGE gels, the dominant protein bands with molecular weight (MW) 28 and 38 kDa were observed in the vaccine bulks (Figure 4A, lanes 2 & 3). From our previous studies [10,19,21,22,25], protein bands with MW 38 and 28 kDa correspond to VP0/VP1 and VP2, respectively. Since the gel was loaded with the same amount of vaccine bulk based on protein concentration (2 µg per lane), it was suggested that Lot #1

contained more VP0/VP1 and VP2 antigens than Lot #2. This observation is consistent with the ratio of VP2 epitope/total protein found in Lots #1 (3.74) and #2 (2.59). The vaccine bulks were further analyzed by Western blot using two monoclonal antibodies (MAb) with different specificity: MAB979 recognizes an epitope of VP2, while N1 reacts with VP1 [21,22,25] As shown in Figures 4B and C, both MAb recognized similar antigen patterns in both Lots #1 and 2. We observed similar Western blot results from Lot #3 (data not shown). These results indicate that the antigen patterns of EV71 vaccine bulks were produced consistently throughout the current manufacturing process.

Mouse immunogenicity studies summarized in Table 2 revealed that the formalin-inactivated EV71 virions were highly potent in eliciting virus neutralization titer that were correlated with VP2 epitope units [10,19,21,22,25]. Although the neutralization titer was decreased (2- to 14-fold), sera from mice immunized twice with EV71 vaccine bulk were capable of cross-neutralizing other isolates from B4, B5 sub-genotype and C4 genotype (Table 2).

The results of other animal (rats, rabbits and macaques) immunogenicity studies are shown in Table 2. Sera from the immunized animals were found to have strong cross-neutralization titer against other B subgenotypes and C genotypes of EV71. Our current results are consistent with the conclusions reported by both Bek *et al.* and Dong *et al.*, [26,27]. They had produced formalin-inactivated EV71 vaccine candidates based on C4 genotype virus that could elicit cross-genotypes neutralizing antibody responses in mouse and non-human primate models [26,27]. They suggest that the common neutralization epitopes of EV71 virus are most likely conformational that could elicit strong cross-neutralizing antibody responses against different EV71 genotypes.

Stability profiles of vaccine bulks and formulated vaccine candidates

The stability profile of 2 different lots of EV71 vaccine bulks based on protein assay and VP2 Q-ELISA are summarized in Table 3. After 1 year of storage at either 4 or 25°C, there was no sign of protein loss in the vaccine bulk. VP2 epitope in both vaccine bulk lots remained relatively stable at

4°C, but there was trend of epitope loss after 1 and 3 months at 25°C storage for Lot #1 and 3, respectively. Based on Western blot analyses using two different monoclonal antibodies N16 specific for the N-terminal peptide of VP1 and MAB979 specific for VP2 shown in Figure 4B and C, there was no EV71 VP1- or VP2-specific protein degradation (no protein fragments with MW below either VP1 and/or VP2 were observed) in the vaccine bulks Lot #1 and 3 stored at 4°C for 12 months. Mouse immunogenicity studies with both vaccine bulks stored at 4°C for 0, 1, 2 and 3 months (2 x 2 µg/dose immunization at 2 weeks apart) revealed that these samples were highly immunogenic and elicited similar geometric mean titer (GMT) of virus neutralization against E59 vaccine strain ranging from 200 to 600 (data not shown). No contamination was observed in all sterility tests. Together, these stability profiles indicate that the EV71 vaccine bulks produced from the current manufacturing process stored at 4°C for 1 year are sterile, stable, and immunogenic in mice.

The vaccine products were analyzed using a Hitachi H-7650 electron microscope according to previously reported protocols [10], some free inactivated EV71 particles were observed and not absorbed onto the alum (data not shown). When the kinetics of vaccine absorption to alum were examined, >50% of protein in the EV71 vaccine product was absorbed within 1 hour after mixing the vaccine bulk with the aluminum phosphate at room temperature. The current data from 3 and 6 months storage also confirm that the rate of alum absorption is more efficient at 25°C in both Lot #1 and 3 (Table 4). In addition, it seems that the virus neutralization titers elicited in mice immunized with the EV71 vaccine product were correlated with the percentage of protein absorbed to alum, particularly in Lot #3 (913 vs. 400 at 4°C and 850 vs. 335 at 25°C). The stability profile of the EV71 vaccine product is supported by no obvious losses of IgG and virus neutralization titers in mouse immunogenicity studies. In the current 18-month stability program, the mouse immune responses also reveal that the EV71 vaccine products from both lots are highly stable for long term storage at 4°C. Finally, no contamination was observed in sterility tests performed at 0, 3, 12 and 18 months.

Conclusion

Based the current results, the pilot scale manufacturing process of cell-based EV71 vaccine has been successfully developed, optimized, characterized, and quantified. In the up-stream process development, VP-SFM serum-free medium was identified to be the optimal medium for Vero cell growth and EV71 virus production. Gel filtration chromatography was found to be the most cost-effective for downstream purification, resulting in overall virus yields as high as 57% (Table 1). The formalin-inactivated virion vaccine candidate was found to be stable >18 months at 4°C. At microgram-levels, viral proteins formulated with alum adjuvant could induce strong virus-neutralizing antibody responses in mice, rats, rabbits, and non-human primates. These results provide valuable information supporting the current EV71 vaccine candidate going into human Phase 1 clinical trials.

Acknowledgements

This work was supported by a grant (No. 98A1-VCSP01-014) from the National Science Council (NSC) of Taiwan.

References

1. Ho, M, Chen ER, Hsu KH, Wu SJT, Chen KT, et al. (1999) **The Taiwan Enterovirus Epidemic Working Group**. An epidemic of enterovirus 71 infection in Taiwan. *N Engl J Med*. 341:929-935.
2. McMinn PC (2002). An overview of the evolution of enterovirus 71 and its clinical and public health significance. *FEMS Microbiol Rev* 26:91-107.
3. Xu J, Qian Y, Wang S, Serrano JMG, Li W, et al. (2010) An emerging infectious disease vaccine target in the Far East? *Vaccine* doi:10.1016/j.vaccine.2010.03.003.

4. Lee MS, Chang LY (2010) **Development** of enterovirus 71 vaccines. *Expert Rev Vaccines* 9:149-156.
5. Solomon T, Lewthwarte P, Perera D, Cordosa MJ, McMinn P, Ooi MH. (2010) *Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet. Infect Dis.* 10:778-90.
6. Huang ML, Ho MS, Lee MS (2011) Enterovirus 71 vaccine: when will it be available? *J. Formos Med Assoc.* 110:425-27.
7. Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. *J Infect Dis* 129:304-9
8. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. *Vaccine* 26:1855-62.
9. Brown, BA, Pallansch MA (1995) Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. *Virus Res* 39:195-205.
10. Liu CC, Guo MS, Lin FHY, Hsiao KN, Chang KHW, et al. (2011) Purification and characterization of EV71 viral particles produced from Vero cell grown in a serum-free microcarrier bioreactor system. *PLoS ONE* doi:10.1371/journal.pone.0020005.
11. Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P et al. (2008) Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. *J. Clin. Microbiol* 46:3192-3200.
12. Chan YF, Sam IC, Abubakar SC (2010) Phylogenetic designation of EV71 genotypes and subgenotypes using complete genome sequences. *Infection, Genetics and Evolution* 10:404-12.
13. Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in Taiwan: Dynamics of genetic and antigenic evolution from 1998 to 2008. *J Clin Microbiol* 47:3653-3662.

14. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. *Nature Med* 15:794-797.
15. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. *Nature Med* 15:798-801.
16. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS (2002) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. *Vaccine* 20: 895-904.
17. Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. *Vaccine* 25:19-24.
18. Tung WS, Bakar SA, Sekawi Z, Rosli R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. *Genet Vaccines Ther* 5:6.
19. Chang JY, Chang CP, Tsaia HHP, Lee CD, Lian WC, et al. (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. *Vaccine* 30:703-711.
20. Reed LJ, Muench H (1938) A simple method of estimating 50 percent end-points. *Am J Hyg* 27:493-497.
21. Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, et al. (2011) Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process. *J Virol Methods*. doi:10.1016/j.jviromet.2011.06.001.
22. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of EV71. *Vaccine*; 29:4362-73.
23. Panezutti H, James O, Hansen EJ, Choi Y, Harkness RE, et al. (1993) Identification of surface-exposed B-cell epitopes recognized by *H. Influenzae* type b P1-specific monoclonal antibody. *Infect Immun* 61:1867-1872.
24. Wu SC., Liu CC, Lian WC (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. *Vaccine* 22:3858-64.

25. Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, et al (2011) Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genotype B isolates. *J Virol Methods* 173:189-95.
26. Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, et al. (2011) Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. *Vaccine* 29:4829-38.
27. Dong C, Liu L, Zhao H, Wang J, Liao Y, et al. (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. *Vaccine* 29:6269-75.

Figure Legends

Figure 1. The growth profiles of Vero cell grown in serum-containing medium (SC) and different serum-free media (SF). Vero cells (2×10^5 cell/ml) was cultured in 75T-flask and counted for viable cell number every 24 hours (0, 24, 48, 72, 96, 120 and 144 hours). The conditions for cell culture were described in the Materials and Methods section.

Figure 2. The optimization of the up-stream process for EV71 virus production. (A) The T-flask was seeded with either $1.0 \sim 1.5 \times 10^6$ or $2.0 \sim 2.5 \times 10^6$ Vero cells, then after 2-3 days the cells were infected by the different ratio of E59/EV71 virus. The effects of different M.O.I were detected in the kinetic profile of virus produced from Vero cell grown in the VP-SFM medium. (B) The consistency of 3 Lots of EV71 virus production in the roller bottles. Virus titer was detected every day by TCID₅₀ for 5 days.

Figure 3. The temperature effect in the kinetic of formalin-inactivation of EV71 virus. Purified E59/EV71 was inactivated by 0.025% (v/v) formalin at different temperature and the residual of virus infectivity was detected by plaque assay performed triplicate at different time points.

Figure 4. The stability profiles of different Lots of EV71 vaccine products stored at 4 °C for various time and analyzed by SDS-PAGE (Panel A) and Western blot (Panel B & C). Lane M is MW Markers; lane 1 is EV71 vaccine product produced from serum-containing medium and stored at 4 °C for 26 months; lanes 2 and 3 are EV71 vaccine products derived from Lot #1 and 2 and stored at 4 °C for 13 and 4 months, respectively. Monoclonal antibody used in the Panels B and C are MAB979 specific for VP2 and N16 specific for VP1, respectively.

Table 1. Summary of in-process characterizations of EV71 vaccine bulk produced from serum-free medium.

Lot #	Process step	Total volume (L)	TCID ₅₀ ^a (x10 ⁶ /mL)	Total Protein ^b (µg/mL)	VP2 epitope ^c (Unit/mL)	Recovery ^d (%)	VP2 epitope/Total Protein (Unit/µg)
Lot #1	Harvest	41.0	11.7	1459.8 +/- 5.5	11.9 +/- 0.8	100	0.008
	Dif/Con ^e	1.10	38.9	825.6 +/- 9.5	531.0 +/- 14.5	119.7	0.64
	LC ^f	0.75	37.2	74.5 +/- 0.8	181.3 +/-16.7	27.9	2.43
	Formalin Inactivated	0.75		53.0 +/- 1.5	198.4 +/- 21.3	30.5	3.74
Lot #2	Harvest	40.0	6.31	1373.1 +/- 29.1	7.73 +/- 0.23	100	0.006
	Dif/Con	1.20	87.1	1351.7 +/- 13.6	249.0 +/- 12.47	96.6	0.18
	LC	0.88	31.4	64.4 +/- 0.89	130.4 +/- 9.07	37.1	2.02
	Formalin Inactivated	0.80		50.3 +/- 1.27	130.4 +/- 6.7	33.9	2.59
Lot #3	Harvest	40.7	10.5	1318.7 +/- 27.6	8.1 +/- 0.31	100	0.006
	Dif/Con	1.00	223.9	1333.4 +/- 32.3	338 +/- 17.5	103.9	0.25
	LC	0.88	104.7	62.0 +/- 0.74	214.4 +/-25.1	57.0	3.46
	Formalin Inactivated	0.85		60.7 +/- 2.82	167.0 +/- 7.43	43.1	2.75

ND: not determined.

^aTCID₅₀ is the median tissue culture infective dose of EV71 that produces pathological cytopathic effects (CPE) in 50% of inoculated cell cultures.

^bTotal protein concentration was determined by the BCA protein assay.

^cVP2-specific epitope content was determined by Q-ELISA [19].

^dRecovery was calculated using the total VP2 epitope content at each step divided by the total VP2 epitope at the harvest stage.

^ediafiltration/ concentration step.

^fgel-filtration chromatography purification.

Table 2. Immunogenicity studies of EV71 vaccine bulks

Animal Model	Vaccine Lot #	Total proteins (µg/dose)	VP2 Q-ELISA unit/dose	IgG Titer (GMT)	TCID ₅₀ Neutralization titer (GMT)			
					B4/E59	B4/S0302	C4	B5
BALB/c Mouse	1	2	7.5	4,525	443	256	32	128
	2	2	5.2	2,934	233	ND*	64	256
	3	2	5.5	2,851	234	ND	ND	ND
Rat	2	10	26	12,800	654	ND	64	128
Rabbit-G1	1	5	18.8	>32,000	13,573	5,677	8,192	5,677
Rabbit-G2	1	10	37.6	>32,000	13,318	ND	13,520	16,384
Rabbit-G3	2	5	13	>32,000	17,093	ND	ND	ND
Rabbit-G4	2	10	26	>32,000	19,308	ND	ND	ND
Macaque	1	10	37.6	>32,000	5,623	ND	5,623	3,169
Macaque	3	5	13.8	25,600	3,169	ND	ND	ND
Macaque	3	10	27.6	25,600	8,912	ND	ND	ND

Eight mice per group and 5 rats per group were immunized twice with formalin-inactivated EV71 virion formulated with alum. Two rabbits per group and individual macaques were immunized three times with formalin-inactivated EV71 virion formulated with alum. The immunization protocol, IgG tier and virus neutralization assay are described in the Materials and Methods section.

* not done.

Table 3. Stability profiles of EV71 vaccine bulks.

Time	Vaccine Bulk Lot #1 stored at different temperature				Vaccine bulk Lot #3 stored at different temperature			
	Total protein (mcg/mL)		VP2 epitope (Unit/mL)		Total protein (mcg/mL)		VP2 epitope (Unit/mL)	
	4°C	25°C	4°C	25°C	4°C	25°C	4°C	25°C
Initial	57.01	57.01	198.35	227.54	48.76	48.76	199.80	199.80
2 weeks	ND	60.73	ND	181.65	ND	50.86	ND	209.55
1 month	58.75	58.25	198.29	150.59	47.74	48.46	206.02	191.36
3 month	58.55	60.50	168.69	156.76	52.59	51.31	192.48	170.48
6 month	57.70	59.27	188.05	137.49	52.19	53.76	190.29	168.52
9 month	58.75	ND	180.35	ND	51.54	51.07	218.64	145.36
12 month	47.76	ND	174.03	ND	46.18	ND	214.39	ND

The total protein and VP2 antigen content in the vaccine bulks were determined by BCA method and VP2 Q-ELISA, respectively.

Table 4. Stability profiles of EV71 vaccine products (70 µg of formalin-inactivated EV71 virion formulated with 9 mg of aluminum phosphate in 3 mL of PBS).

Time		Lot #1			Lot #3		
		Unabsorbed Protein (µg/mL)	IgG (GMT ± SE)	Neutralization Titer (GMT ± SE)	Unabsorbed Protein (µg/mL)	IgG (GMT ± SE)	Neutralization Titer (GMT ± SE)
Initial		23.3	4525 ± 705	443 ± 279	23.3	2934 ± 705	233 ± 99
1 month		6.57 ± 0.16	1037 ± 316	153 ± 52	8.56 ± 0.30	1131 ± 176	265 ± 27
2 month		7.69 ± 0.35	2075 ± 353	105 ± 89	9.77 ± 0.04	1903 ± 262	246 ± 14
3 month	4°C	7.15 ± 2.58	1600 ± 330	120 ± 58	9.34 ± 1.19	2263 ± 302	400 ± 88
	25°C	5.00 ± 0.01	2075 ± 353	269 ± 110	6.46 ± 0.12	3200 ± 761	913 ± 125
6 month	4°C	8.25 ± 0.22	1345 ± 280	79 ± 29	9.88 ± 0.11	2691 ± 262	335 ± 83
	25°C	5.36 ± 0.23	1745 ± 300	262 ± 122	7.07 ± 0.37	3200 ± 659	850 ± 122
9 month		5.59 ± 0.08	2986 ± 413	534 ± 90	8.00 ± 0.19	3200 ± 0	1089 ± 187
12 month		5.87 ± 0.06	4222 ± 523	301 ± 86	8.00 ± 0.20	3676 ± 427	349 ± 85
18 month		7.03 ± 0.51	1393 ± 227	534 ± 77	8.82 ± 0.83	2599 ± 244	643 ± 97

Eight mice per group were immunized twice with 0.2 mL of EV71 vaccine products Lot #1 and 3 that were stored in stability study chambers with different pre-set temperatures. The immunization protocol, IgG tier and virus neutralization assay are described in the Materials and Methods section.

February 17, 2012.

Dear Professor Yi Guan:

First of all, we thank you and reviewers for your diligent effort to evaluate the credibility and the potential values of our paper. Please find below our responses to the Reviewers' comments:

Reviewer #1:

This study by Chou et al. describes the development of an enterovirus 71 (EV71) vaccine at a pilot scale based on the serum-free growth of EV71 in Vero cells and its subsequent inactivation and purification. The authors have demonstrated that an inactivated EV71 E59 vaccine (genotype B4) elicit a strong neutralising response not only against genotype B4 but also cross-reacting activity against other EV71 genotypes. Although this is not a ground-breaking area of research, and similar publications have already been described recently (Bek et al 2011, Dong et al 2011, cited within the text), I consider this paper an interesting piece of data for both clinical and non-clinical researchers working in the field. EV71 is a very important human pathogen of tremendous relevance for the global public health, and the development of efficient vaccines to control it represents an important step forward. In summary, the experiments have been properly conducted and support the conclusions reached by the authors.

However, the paper is very poorly written. Apart from considerable grammatical errors across the text, there are loads of typos and other non-grammatical mistakes which suggest the authors have not paid sufficient attention during the preparation of this manuscript. As an example: part of the text (page 4) is in a red coloured font and especially very bad written (it seems to have been directly copied from elsewhere), references 2 and 3 show typos in the publication dates (years 010 and 202?), and figure 5 cited in the text does not appear attached to the text. The authors may want to improve the clarity and the quality of the text to be considered for its publication in PLoS ONE. Additionally, I have also other concerns affecting the scientific data presented here that should be addressed by the authors.

Response: We thank the Reviewer pointing out our mistakes that have been corrected. It is a typo error, the figure 5 should be written as the figure 4. The revised manuscript has been edited by an English speaking scientist.

My final decision is timidly recommend this paper with the condition of making large improvements in the text and answering the several major critique points listed below.

Major points:

1. *The manuscript introduction lacks a detailed description on the EV71 and/or picornavirus capsid protein expression, maturation and crystal structure. Within the text you mention VP1, VP2, VP4, VP0 without providing with any background information on these proteins. Special emphasis on VP0 cleavage into VP2 and VP4 as a key capsid maturation step simultaneous to viral RNA encapsidation (at least in other picoviruses) should be provided. References should also be included. No information provided either on the actual EV71 cellular receptors (and other picornaviruses). I think this information is relevant for putting the data within context.*

Response: The comment from the Reviewer is well taken, so we have added the information and references into the Introduction section (red color). The cleavage of VP0 into VP2 and VP4 has been shown as a key capsid maturation step and also is important to viral RNA encapsidation [8,10]. Two different membrane proteins, human P-selectin glycoprotein ligand-1 (PSGL-1) [14] and human scavenger receptor class B, member 2 (SCARB2) [15] have been identified as cellular receptors for EV71. Transgenic mice carrying these genes are being engineered and should be useful for HFMD vaccine development.

2. *Experiment in Figure 2A is not well explained. Sentence in page 10 is terribly confusing. Do you mean you seeded this amount of cells or that you infected that amount of cells? They represent different scenarios and a different interpretation can be made. Anyway, it is a bit contradictory that only a 2-fold difference in the number of cells resulted in 10-fold differences in virus titres at different time points. Were these TCID50 carried out in triplicate? If so, I'd suggest carrying out a replica of this experiment to show if the same effect can be reproduced.*

Response: We thank the Reviewer pointing out the unclear statement. In the revised manuscript, we re-write the figure legend of Figure 2A: The T-flask was seeded with either $1.0\sim 1.5 \times 10^6$ or $2.0\sim 2.5 \times 10^6$ Vero cells, then after 2-3 days the cells were infected by the different ratio of E59/EV71 virus.

3. *In Figure 3, inactivation at 25 C has been adjusted to a line, but it seems not to follow linear progression. I think it would be more precise to calculate the inactivation tendency and kinetics only with later time points (from 24 hours onwards) or alternatively adjust the inactivation kinetics to a curve.*

Response: We have revised the figure 3 according to the Reviewer's suggestion and calculate the inactivation tendency and kinetics only with later time points (from 24 hours onwards). Therefore, the time required for full inactivation will be 12.6 days for 25 C. We have revised this new data in the text.

4. Page 15, line 22. It is claimed that virus titer is decreased 2- to 8-fold in cross-neutralization experiments. Nevertheless, if I am not wrong, sera from BALB inoculated with lot 1, presented 14-fold differences in neutralizing reference E59 strain with respect to B5 strain. Please clarify this point.

Response: We thank the Reviewer pointing out the mistake in calculation. We revised the sentence: Although the neutralization titer was decreased (2- to 14-fold), sera from mice immunized twice with EV71 vaccine bulk were capable of cross-neutralizing other isolates from B4, B5 sub-genotype and C4 genotype (Table 2).

5. Vaccine lots present a large proportion of VP0 which is comparable to the levels detected of VP2. This fact suggests that about a 50% of capsid proteins are incompletely mature. In other picornaviruses it has been demonstrated that RNA encapsidation is coetaneous to VP0 cleavage into VP2 and VP4 and subsequent capsid maturation. It would be interesting to demonstrate if vaccine lots used contain only capsids or they are mixtures of capsids and unassembled pentamers. I'd recommend carrying out a WB analysis with further purified samples, e.g: ultra-pure EV71 mentioned in page 13, line 42, to determine if VP0 is present in unassembled capsid units or if also found in full-capsid structures.

Response: The Reviewer is totally right on the issue that we found infectious EV71 viruses produced from the Vero cells grown in serum-free medium to be around 30% compared to the defective viral particle. As shown in Figures 2 and 3 of our previous report [10], the purified infectious EV71 virus was found to consist of all 4 structural proteins VP1, VP2, VP3 and VP4. In contrast, VP0, VP1 and VP3 protein bands were found to be the major components in the defective viral particles in the SDS-PAGE and Western blot analysis.

6. NO FIGURE 5!!!! Please upload it.

Response: It is a typo error, the figure 5 should be written as the figure 4.

Minor points:

- *Page 4: Change to black font. Remove list numbers and change the text to past tense. Include animal experiments procedures with mice, rat and rabbit elsewhere.*

Response: We had revised the monkey experimental procedure according to the Reviewer's suggestion.

- *Page 6, line 1. Change inoculated by seeded. Line 2, At each time point, cell culture was performed??. This sentence makes no sense. Please clarify. Line 5, change cell counts were performed by cell counting was performed. Line 16, Do you want to mean 'EV71 stocks were produced using the roller bottle technology AND purified using?..*

Response: We thank the Reviewer pointing out our mistakes. We had revised the procedure according to the Reviewer's suggestion.

- *Page 6, 7 and along the text, performed is constantly and redundantly used. You may want to use synonyms such as carry out, develop?*

Response: We had revised the manuscript according to the Reviewer's suggestion.

- *Page 7 and through the rest of the manuscript, many sentences finish without a dot. Please correct this.*

Response: We had revised the manuscript according to the Reviewer's suggestion.

- *Page 7, line 42. Use abbreviation for millilitre (mL). Page 8, line 32. Diluted. Page 10, line 52. The highest virus titer WAS 2 x 10⁷.*

Response: We had revised the manuscript according to the Reviewer's suggestion.

- Page 14, line 10. I suggest replacing 'no infectious EV71 particle was observed' by 'no infectivity was detected'. Line 15, I'd remove particle since this cannot be physically observed.

Response: We had revised the sentence according to the Reviewer's suggestion.

- Page 15, lines 34-42. This sentence is grammatically wrong. Please amend it.

Response: We had revised the manuscript according to the Reviewer's suggestion. "The titers of infectious virus particles in the supernatants harvested from three cGMP lots were found to be 11.70, 6.31, and 10.5×10^6 TCID₅₀ units per mL for Lot #1, 2, and 3, respectively (Table 1). VP2 epitope contents were measured by Q-ELISA and found to be 11.9, 7.73, and 8.1 units of VP2 per mL in Lot #1, 2, and 3, respectively".

- Page 16, lines 29-32. This sentence makes no sense. Amend it.

Response: We had revised the sentence according to the Reviewer's suggestion. "These results suggest that the un-assembled VP2 antigens were not removed from the virus concentrate at the 100 kDa TFF step".

- Too many typos within the References section. I recommend the authors to use a citation tool programs (i.e. Endnote or similar).

Response: We had revised the manuscript according to the Reviewer's suggestion.

- Figure legends are poor. Please include more information about the experiments carried out in each of them. Improve the quality in Figures 1, 2A, 2B, 3. Please use the same font type and size following indications provided in PLoS ONE guidelines. Please use internationally accepted units in the abscissa (1.E+05 is not a valid measure unit).

Response: We had re-written the figure legends and improved the quality of figures in the revised manuscript according to the Reviewer's suggestion.

Reviewer #2: The authors describe the production of Enterovirus 71(EV71) vaccine candidate and monitoring of the production steps by infectious titer, total protein concentration and Vp2 content.

My questions are as follow:

1. Why didn't the authors use the bioreactor system and cytodex beads to grow the virus like they did in the referenced papers(see ref. 17 in the draft) instead of flasks and roller bottles.

In the papers and also related papers they pretty much characterized the vero cell-EV71 system in the same serum-free medium. Maybe simply it is timing of preparing and submitting the drafts to the different journals.

In regarding with the cells, cells in suspension may be suitable in production of vaccine.

Response: The Reviewer has pointed out our frustration, issues and constraints working in a non-profit organization and funding come from government. In the original EV71 vaccine development program, we would like quickly going into human clinical trials using roller bottle technology to produce EV71 from Vero cell grown in serum-containing medium. In the middle of process development, the reviewers from Taiwan FDA and government funding agents suggested to use the serum-free medium for the cell culture. Therefore, we switched to produce the GMP-grade clinical materials in serum-free medium and reported in this manuscript. The results generated from the serum-containing medium studies were reported in the **reference #19**. Three years ago, our cGMP facility did not have a 30-L Bioreactor for the process development and the 5-L bioreactor used in the Research laboratory was too small for pilot scale production and could not produce enough materials for human clinical trials. For these reason, the first generation of EV71 vaccine is produced from roller bottle and serum-free medium.

2. Any of the monkeys was removed from the study due to sickness or any other reasons for that matter.

Response: No, all monkeys immunized with the EV71 vaccine candidate are healthy and have no problems.

3. Tables 1 and 2 need to be simplified, especially table 1. In the table 1 the unit of total volume says (L), if it's true, 41 liters would be awfully large. I think it's a typo. If it's meant to be mL, then 41mls would be too little, since 200mls per roller bottle were used.

Response: The unit of total volume is **liter** and about 40 liters of virus harvest were produced from each pilot- scale production run (200 x 200 mL).

4. It would be nice to know how many infectious viruses were used to immunize these animals in the table 2.

Response: Since we use formalin-inactivated EV71 vaccine candidate for the immunizations, so there would be no live or infectious viruses. Based on the overall recovery yield, we could estimate each microgram of viral proteins containing 2×10^4 TCID₅₀ infectious unit

5. Have comparison studies between with and without alum adjuvant been done?

Response: We had studied the effect of alum adjuvant in the vaccine efficacy and reported in the **reference #19**. The formalin-inactivated EV71 vaccine candidate formulated in aluminum phosphate (alum) elicited 3 to 5-fold higher virus neutralizing antibody responses in mouse model.

Following are more specific comments:

Page 3, line 41-51 How does formalin-inactivated EV71 in this study relate to heat-inactivated EV71?

Response: We had performed the comparison studies between the formalin-inactivated and the heat-inactivated EV71 vaccine candidates produced from the serum-containing medium, and found the neutralization titers to be similar. There is a problem associated with the heat-inactivated EV71 that could reverse to become infectious again under long term storage. For the safety issue, we select formalin-inactivated EV71 vaccine candidate.

Page 4, line 24 What is SPF?

Response: SPF means specific pathogens free.

*Page 5, line 1 Change from a high-risky pathogen to having a high-risk pathogen. What are high-risk pathogens?
line 41 What is cGMP?*

Response: We had revised the manuscript according to the Reviewer's suggestion. cGMP means current Good Manufacturing Practices.

Page 6, line 2-5 Meaning of "At each time point...in triplicate" is not clear.

Response: We had revised the manuscript: "At each time point, cell counts were performed in triplicate".

Page 8, line 46 "goat anti-rabbit IgG" Shouldn't it be conjugated to some kind of enzyme or labels?

Response: Goat anti-rabbit IgG is conjugated to peroxidase. We had revised the sentence in the manuscript:

Page 10, line 53-56 Were the cells in the roller bottles and/or flasks checked for growth phase? were they formed a confluent layer or sub-confluent layer? Virus yield might have been due to the growth phase of the cells.

Response: The roller bottles were inoculated sub-confluent state and virus was added when there was ~80-90% confluent. The Reviewer could be right that high virus yield might have been due to the growth phase of the cells.

Page 11, line 3-5 MOI is very low to me. The virus was harvested before CPE had appeared? Deliberately avoided CPE due to host proteins?

Response: Yes, the virus was deliberately harvested before CPE to avoid the host proteins contamination.

We hope with all these changes that will be satisfactory to you and the Reviewers.

Best regards.

Pele Chong